WO2015136543A1 - Methods, compositions and devices for treatment of motor and depression symptoms associated with parkinson's disease - Google Patents

Methods, compositions and devices for treatment of motor and depression symptoms associated with parkinson's disease Download PDF

Info

Publication number
WO2015136543A1
WO2015136543A1 PCT/IL2015/050267 IL2015050267W WO2015136543A1 WO 2015136543 A1 WO2015136543 A1 WO 2015136543A1 IL 2015050267 W IL2015050267 W IL 2015050267W WO 2015136543 A1 WO2015136543 A1 WO 2015136543A1
Authority
WO
WIPO (PCT)
Prior art keywords
rasagiline
mao
subject
brain
inhibition
Prior art date
Application number
PCT/IL2015/050267
Other languages
French (fr)
Inventor
Moussa B.H. Youdim
Orly Weinreb
Tamar Amit
Original Assignee
Abital Pharma Pipelines Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abital Pharma Pipelines Ltd. filed Critical Abital Pharma Pipelines Ltd.
Publication of WO2015136543A1 publication Critical patent/WO2015136543A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Definitions

  • the present invention in some embodiments thereof, relates to therapy and, more particularly, but not exclusively, to compositions, methods and devices useful for the treatment of neuropsychiatry conditions or symptoms such as depression and/or neurodegenerative conditions such as Parkinson's disease and/or motor and neuropsychiatric symptoms associated therewith.
  • MAO monoamine oxygen oxidoreductase
  • MAO monoamine oxygen oxidoreductase
  • EC NUMBER EC 1.4.3.4 This enzyme is known as oxidizing primary aliphatic and aromatic amines and some secondary and tertiary amines.
  • the reaction catalyzed by MAO can be represented by the following generalized equation:
  • MAO- A and MAO-B Two isoenzymes of monoamine oxidase are present in most mammalian tissues. These isoenzymes, denoted in the art as MAO- A and MAO-B, were originally distinguished by their sensitivities to inhibition by the acetylenic inhibitors clorgyline and deprenyl and by their substrate specificities.
  • MAO-A catalyzes the oxidative deamination of 5 -hydroxy tryptamine (5-HT)
  • MAO-B is active toward benzylamine and 2-phenylethylamine (PEA)
  • PEO 2-phenylethylamine
  • tyramine and dopamine are substrates for both enzymes in the brain, and the role of MAO enzymes is recognized as regulating the metabolism of catecholamine neurotransmitters (e.g., dopamine and noradrenaline) and serotonin.
  • catecholamine neurotransmitters e.g., dopamine and noradrenaline
  • serotonin e.g., serotonin.
  • a list of exemplary substrates of MAO-A and/or MAO-B is presented, for example, in Tipton et al., "Monoamine oxidase: functions in the central nervous system", In Encyclopedia of Neuroscience, Adelman, G; B. Smith, B, Eds:. Elsevier
  • MAO-A and/or MAO-B in peripheral tissues such as the intestine, liver, lung, and placenta appear to play a protective role in the body by oxidizing vasoactive amines from blood or preventing their entry into the circulation.
  • intraneuronal MAO-A and MAO-B have been suggested to protect neurons from exogenous amines and/or to regulate levels of neurotransmitter amines synthesized within a neuron.
  • MAO-A selective or nonselective irreversible MAO inhibitors has been limited because individuals taking these drugs become susceptible to amines, such as tyramine, in the diet. These amines are normally degraded by MAO in peripheral tissues. When MAO is inhibited, ingested tyramine can enter the blood, from which it is taken up by adrenergic nerve terminals releasing stored noradrenaline and resulting in a hypertensive response (hypertensive crises). On the basis of the high concentrations of tyramine in some cheeses, this hypertensive response to dietary amines is widely known as the "cheese reaction" or "cheese effect”. Tyramine is found in high concentration also in other food nutrients.
  • MAO-B inhibitors such as (-)-deprenyl (Selegiline) exhibit no effect in patients suffering from endogenous depression, and further have a very low interaction with tyramine when given either orally or intravenously.
  • MAO inhibitors were found to be highly potent protectors against MPTP (l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine) neurotoxicity, which gives rise to a condition resembling idiopathic Parkinson's disease. Inhibitors of MAO are therefore considered to prolong the actions of dopamine in Parkinson's disease.
  • Parkinson's disease is a slowly progressive neurodegenerative disorder. It is characterized by motor symptoms, such as bradykinesia, rigidity, tremor at rest and postural instability, which are associated with degeneration of the nigrostriatal dopaminergic projection originating in the substantia nigra (SN). In addition to these motor symptoms, non-motor symptoms, such as olfactory dysfunction, can be observed even prior to the manifestation of motor symptoms in PD patients.
  • Depression is a common psychiatric comorbidity in PD, affecting more than 60 % of the patients.
  • Pharmacotherapy for depression in PD entails special concerns related to different side effects of the various anti-depressants and great potential for drug-drug interaction.
  • Selective serotonin reuptake inhibitors (SSRIs) are typically prescribed, however with often insufficient results.
  • Selegiline also referred to in the art as Anipryl, (-)-deprenyl, L-deprenyl, Eldepryl, Emsam, Zelapar
  • Rasagiline N-propargyl-l-(R)-aminoindan; Marketed as Azilect®
  • PD Parkinson's disease
  • MDD Major Depressive Disorder
  • Both drugs are orally- administered drugs, and are subject to extensive first pass hepatic metabolism, resulting in poor and highly variable oral bioavailability (35 % for Rasagiline and 4-10 % for Selegiline).
  • Rasagiline and Selegiline are preferential MAO-B inhibitors, their selectivity is dose-dependent; While Selegiline is approved for the treatment of depression, the dose is 3- to 6-fold higher than that for the treatment of PD, causing loss of MAO-B selectivity and requiring precautions to prevent hypertensive crises due to "cheese reaction".
  • Rasagiline is a new MAO-B inhibitor, introduced in 2006, that has 3- to 16-fold greater potency than Selegiline. Similarly to Selegiline, Rasagiline is generally devoid of potential to cause hypertensive crises, the "cheese reaction", unless administered at high concentrations that are sufficient to inhibit MAO-A [Youdim and Bakhle, 2006, Br J Pharmacol., 2006, 147 Suppl 1, S287-296].
  • the recommended dose of rasagiline for humans is 1 mg once daily when used alone (monotherapy), and 0.5-1 mg once daily when combined with 1-DOPA. Patients with mild liver disease should not use more than 0.5 mg daily.
  • patients administered with Rasagiline are typically cautioned to avoid tyramine rich food, as well as administration of anti-depressants of the selective serotonin uptake inhibitors family, serotonin-norepinephrine uptake inhibitors family and other MAO inhibitors.
  • Rasagiline is primarily metabolized by hepatic cytochrome P-450 to form its major metabolite, l-(R)-aminoindan, a non-amphetamine, weak reversible MAO-B inhibitor compound.
  • one of the Selegiline principal metabolites is 1-methamphetamine which can be converted to 1- amphetamine. See, for example, Bar Am et al., Journal of Neurochemistry, 2010, Vol. 11, pp. 1131-1137; Weinreb et al, Antioxidants & Redox Signaling, Volume 14, Number 5, 2011, page 767.
  • Intranasal administration is a noninvasive means for targeting the brain bypassing the blood-brain barrier (BBB), minimizing systemic absorption, and limiting potential peripheral side effects [Vyas et al., Current drug delivery, 2005, 2, 165-175; Ilium, 2004, The Journal of pharmacy and pharmacology, 2004, 56, 3-17].
  • BBB blood-brain barrier
  • MAO-B inhibitors such as Rasagiline are useful in the treatment of Parkinson's disease, particularly in alleviating motor symptoms associated with Parkinson's disease, a need still remains to treat depression symptoms associated with this disease. Such a need becomes even more pronounced due to adverse drug-drug interactions between Rasagiline and commonly used anti-depressants such as SSRIs, and while considering the depression symptoms associated with a majority of Parkinsonian patients.
  • MAO-B inhibitors such as, for example, Rasagiline and Selegiline, may act also as anti-depressants at higher doses, due to MAO-A inhibition, administration of these drugs at doses effective in treating MAO-A inhibition is limited by the "cheese reaction" (hypertensive crisis) associated with such high doses.
  • Rasagiline and Selegiline are prescribed for the treatment of Parkinson's disease at doses which are selective to MAO-B inhibition and are therefore ineffective in treating depression symptoms in Parkinsonian patients.
  • a MAO-B inhibitor such as Rasagiline is administered into the brain at a range of doses, which are capable of treating neuropsychiatric conditions such as depression and/or alleviating neuropsychiatric (e.g., depression) symptoms (e.g., symptoms associated with Parkinson's disease).
  • administering a MAO-B inhibitor such as Rasagiline to the brain of a subject results in alleviating or treating both motor and depression symptoms associated with Parkinson's disease.
  • This methodology is effected while utilizing Rasagiline or any other MAO-B inhibitor, at doses sufficient to inhibit MAO-A in the brain, possibly without potentiation of sympathetic cardiovascular activity (e.g., "cheese reaction").
  • Such a methodology allows using drugs such as Rasagiline for exhibiting antidepressant activity (e.g., due to MAO-A inhibition), and particularly, for exhibiting a dual effect of MAO-A and MAO-B inhibition, thereby improving the effect of the drug in patients suffering from Parkinson's disease by alleviating both motor and depression symptoms associated with the disease.
  • the present inventors have demonstrated that intranasal administration of Rasagiline at a range of doses, results in both MAO-A and MAO-B inhibition in the brain, whereby similar doses, when administered intraperitoneally (IP) or orally, are inefficient in inhibiting MAO-A in the brain.
  • IP intraperitoneally
  • the present inventors have further demonstrated that intranasal administration of Rasagiline at a range of doses, results in efficient inhibition of MAO-A and MAO-B in the brain, yet in inefficient inhibition of MAO-A in the periphery (e.g., liver and small intestine).
  • the methodology described herein can therefore be utilized optionally for administering to a subject in need thereof a therapeutically effective amount of a MAO-B inhibitor such as Rasagiline such that a ratio between inhibition of MAO-A in the brain and inhibition of MAO-A in the periphery is higher than the respective ratio that is obtained by oral administration of Rasagiline.
  • a MAO-B inhibitor such as Rasagiline
  • the methodology described herein therefore provides for a triple effect: treating motor disorders or symptoms, such as symptoms associated with Parkinson's disease, treating a neuropsychiatric condition such as depression, for example, depression symptoms associated with Parkinson's disease, and obviating the "cheese effect" which is otherwise associated with administration of MAO-A inhibitors.
  • a method of treating motor and neuropsychiatric symptoms associated with Parkinson's disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of Rasagiline or a pharmaceutically acceptable salt thereof, wherein the administering is effected by intranasal administration.
  • a method of treating a neuropsychiatric condition such as depression in a subject in need thereof comprising administering to the subject a therapeutically effective amount of Rasagiline or a pharmaceutically acceptable salt thereof, wherein the administering is effected by intranasal administration.
  • the depression is associated with Parkinson's disease.
  • a method of treating a neuropsychiatric condition and/or a neurodegenerative condition in a subject in need thereof comprising administering to the subject a therapeutically effective amount of Rasagiline or a pharmaceutically acceptable salt thereof, wherein the administering is effected by intranasal administration.
  • the condition is treatable by l-(R)-aminoindan.
  • the amount of Rasagiline or a salt thereof is such that inhibits at least 50 % of an activity of MAO-A in the brain of the subject.
  • the amount of Rasagiline or a salt thereof is such that inhibits at least 80 % of an activity of MAO-A in the brain of the subject.
  • Rasagiline or a salt thereof is such that a ratio of the inhibition of an activity of brain MAO-A to inhibition of an activity of peripheral MAO-A is higher than 1.
  • the Rasagiline or a salt thereof is administered as a pharmaceutical composition which further comprises a pharmaceutically acceptable carrier.
  • the composition is in a form of a powder.
  • composition and/or a mode of the intranasal administration are configured such that following the administering, an amount of rasagiline in the brain of the subject is such that inhibits at least 50 % or at least 80 % of an activity of MAO-A in the brain.
  • composition and/or a mode of the intranasal administration are configured such that following the administering, an amount of rasagiline in the brain of the subject is such that a ratio of the inhibition of an activity of brain MAO-A to inhibition of an activity of peripheral MAO-A is higher than 1.
  • the amount of rasagiline or a salt thereof is equivalent to an amount that ranges from 0.2 mg/kg per day to 6 mg/kg per day in rats.
  • the subject is a human and the amount of rasagiline or a salt thereof is higher than 2 mg per day.
  • a pharmaceutical composition comprising Rasagiline or a pharmaceutically acceptable salt thereof, the composition being formulated for intranasal administration.
  • the composition is in a form of a powder.
  • the composition is identified for use in treating or alleviating any one of the conditions and/or symptoms as described herein.
  • Rasagiline or a pharmaceutically acceptable salt thereof in the manufacture of a pharmaceutical composition (medicament) for treating or alleviating any one of the conditions and/or symptoms as described herein.
  • a system for intranasal administration of Rasagiline or a pharmaceutically acceptable salt thereof to a subject in need thereof comprising means for dispensing a pre-determined dose of Rasagiline or the salt thereof and for intranasally delivering the dose, the pre-determined dose being effective for alleviating neuropsychiatric and motor symptoms associated with Parkinson's disease.
  • a system for intranasal administration of Rasagiline or a pharmaceutically acceptable salt thereof to a subject in need thereof comprising means for dispensing a pre-determined dose of Rasagiline or the salt thereof and for intranasally delivering the dose, the pre-determined dose being effective for treating neuropsychiatric and/or neurodegenerative conditions in a subject in need thereof, as described herein (e.g., depression).
  • the pre-determined dose is effective for treating depression.
  • a method of treating a neuropsychiatric and/or neurodegenerative condition in a subject in need thereof comprising administering to the subject a therapeutically effective amount of Rasagiline or a pharmaceutically acceptable salt thereof, wherein the administering is effected at a dose and/or a mode of administration selected such that a ratio of the inhibition of an activity of brain MAO-A to inhibition of an activity of peripheral MAO-A in the subject is higher than 1.
  • a system configured for administering Rasagiline or a pharmaceutically acceptable salt thereof to a subject in need thereof, the system comprising means for delivering Rasagiline or the salt thereof to the subject, wherein the means are such that upon delivering Rasagiline or the salt thereof, a ratio of the inhibition of an activity of brain MAO-A to inhibition of an activity of peripheral MAO-A in the subject is higher than 1.
  • the method and system are for use in treating or alleviating any one of the conditions and/or symptoms described herein.
  • FIG. 7 is a bar graph showing the effect of intranasal administration of rasagiline, given in liquid or powder formulations, on the ratio of striatal/small intestinal MAO-A inhibition in acute-treated adult male Sprague Dawley rats. Rats were intranasally administered either with rasagiline in dextrose powder formulation (0.24,
  • FIGs. 11A-B are bar graphs showing the effect of I.N and P.O administration of rasagiline on time in center and distance in OFT. Rats received vehicle (control) or rasagiline, either IN or PO for 3 times a week, for 4 weeks.
  • FIGs. 16A-D are bar graphs showing the effect of IN and PO administration of rasagiline on striatal DA metabolism expressed as the ratios of DOPAC/DA (FIG. 16A), HVA/DA (FIG. 16B) and 3-MT/DA (FIG. 16C).
  • the DA reuptake index was expressed as 3-MT/DOPAC (FIG. 16D).
  • FIGs. 17A-D are bar graphs showing the effect of IN and PO administration of rasagiline on striatal levels of 5-HT (FIG. 17A), its metabolite 5-HIAA (FIG.
  • FIGs. 18A-D are bar graphs showing the effect of IN and PO administration of rasagiline on hippocampal levels of 5-HT (FIG. 18A), its metabolite 5-HIAA (FIG. 18B) and of NE (FIG. 18D), as determined by HPLC analysis.
  • FIG. 19 presents an image of an exemplary intranasal device useful for IN administration of a powder formulation to rats.
  • FIGs. 21A-C are bar graphs presenting the effect of IN rasagiline formulations, powder and liquid, and PO administration, on striatal MAO-A activity (FIG. 21A) and MAO-A inhibition ratios of striatum/liver (FIG. 21B) and striatum/intestine (FIG. 21C).
  • the present invention in some embodiments thereof, relates to therapy and, more particularly, but not exclusively, to compositions, methods and devices useful for the treatment of neuropsychiatry conditions or symptoms such as depression and/or neurodegenerative conditions such as Parkinson' s disease and/or motor and neuropsychiatric symptoms associated therewith.
  • Parkinson's disease is the second most common neurodegenerative disorder, affecting 1-3 percent of people older than 50 years. Parkinson's disease is characterized by motor symptoms, such as bradykinesia, rigidity, tremor at rest and postural instability, which are associated with degeneration of the nigrostriatal dopaminergic projection.
  • Depression is a common and potentially debilitating aspect of Parkinson's disease, affecting 50-70 percent of Parkinsonian patients. Depression in Parkinson's disease is demonstrably different from ordinary major depression in terms of gender ratio, age, symptom profile, comorbidity, and chronicity. Treatment of depression in Parkinson's disease entails special concerns related to side effects and drug-drug interactions.
  • the currently most common drugs for the treatment of Parkinson' s disease are the irreversible selective MAO-B inhibitors (e.g., Rasagiline and Selegiline). These drugs are assumed to exert their primary effect in Parkinson' s disease (PD) by MAO-B inhibition which results in a slower metabolism of endogenous and exogenous dopamine (DA), thus providing symptomatic benefits (Finberg et al. 1996, 1998, supra).
  • MAO-B inhibitors e.g., Rasagiline and Selegiline
  • Irreversible nonselective MAO-AB and selective MAO-A inhibitors are known as anti-depressants.
  • Such drugs can potentiate the cardiovascular effect of the sympathomimetic amine, tyramine, present in many foods. Since tyramine is metabolized by MAO, the inhibition of MAO-A results in uptake of tyramine from circulatory system, which results in hypertensive crisis, known as the "cheese effect", as a consequence of noradrenaline release from peripheral adrenergic neurons by tyramine.
  • Parkinson' s disease at doses in which MAO-B inhibition is exerted may also exhibit MAO-A inhibition, however, at doses which are at least 3-fold higher that those required for exhibiting MAO-B inhibition.
  • Rasagiline when given orally or IP, does not cause a "cheese reaction" at its selective MAO-B inhibitory activity dosage. However, at higher dosage it loses its selectivity and consequently further inhibits MAO-A, thus causing a "cheese reaction”.
  • Rasagiline is also contraindicated with several families of anti-depressants, including for example, the SSRIs. Thus, while treatment of Parkinsonian patients with Rasagiline results in alleviation of motor symptoms associated with the dopaminergic system, such a treatment limits the possibilities of alleviating depression symptoms associated with Parkinson's disease.
  • the present inventors have conceived administering a MAO-B inhibitor such as Rasagiline directly into the brain, at a dose that would affect depression in a subject in need thereof, and hence would affect both motor and depression symptoms associated with Parkinson's disease.
  • a MAO- B inhibitor such as rasagiline
  • the present inventors have envisioned administering a MAO- B inhibitor such as rasagiline at a dose which would inhibit both MAO-A and MAO-B in the brain, yet would not inhibit systemic (peripheral) MAO-A.
  • Such a methodology provides for an efficient treatment of depression and particularly, for an efficient treatment of both motor symptoms and depression symptoms associated with Parkinson's disease, presumably due to MAO-A and MAO-B inhibition in the brain, and avoids inhibition of MAO-A in the periphery and the consequent adverse "cheese reaction".
  • intranasal delivery of rasagiline in e.g., a powder formulation resulted in inhibition of monoamine oxidase (MAO)-A, in rat striatum and hippocampus, following acute treatment.
  • a powder formulation was shown to exhibit a greater efficacy compared to a liquid formulation.
  • the intranasal delivery of rasagiline (0.6 mg/kg in rats) in powder formulation showed a significantly low peripheral MAO- A inhibition (expressed as the striatum/intestine MAO-A inhibitory ratio).
  • the present inventors have further uncovered that intranasal delivery of rasagiline in powder formulation (e.g., 0.24-6 mg/kg in rats) resulted in a dose-dependent MAO-A inhibition in the striatum and hippocampus (up to about 97 % and about 95 %, respectively) in rats.
  • MAO-B was almost completely inhibited (about 98%) in the striatum and hippocampus, at all rasagiline doses analyzed.
  • intranasal delivery of rasagiline in a powder formulation exerted significantly enhanced MAO-A inhibition in both the striatum and hippocampus, as compared to oral administration of rasagiline in acute-treated rats.
  • Rasagiline at both regimens significantly inhibited (about 98%) MAO-B activity in the striatum and hippocampus of acute-treated rats.
  • Intranasal delivery of rasagiline (0.24 and 0.6 mg/kg) in powder formulation resulted in significantly reduced peripheral MAO-A inhibitor, compared to respective doses of oral administration of Rasagiline.
  • intranasal delivery of rasagiline e.g., as a mesylate salt thereof
  • can attain high drug concentrations in the brain that could also inhibit brain MAO-A activity and cause only limited potentiation to induce hypertensive crises ("cheese reaction").
  • intranasal delivery of rasagiline may exert overall beneficial effects of the drug via its active potent neuroprotective/neurorestorative metabolites (propargylamine and 1-R-aminoindan) without periphery side effects.
  • intranasal delivery of rasagiline represents a novel therapeutic approach of the treatment of neuropsychiatric conditions such as depression and/or neuropsychiatric symptoms (e.g., depression) associated with Parkinson's disease.
  • a method of treatment which is effected by administering to the brain of subject a therapeutically effective amount of a MAO-B inhibitor such as Rasagiline.
  • the method is effected by administering to the brain of a subject a MAO-B inhibitor is an amount that is capable of treating a neuropsychiatric condition or symptom in a subject in need thereof.
  • a method as described herein is effected by administering to the brain of a subject a MAO-B inhibitor in an amount that is capable of treating (or alleviating) both motor and neuropsychiatry (e.g., depression) symptoms associated with Parkinson's disease.
  • a MAO-B inhibitor in an amount that is capable of treating (or alleviating) both motor and neuropsychiatry (e.g., depression) symptoms associated with Parkinson's disease.
  • the amount of the MAO-B inhibitor is sufficient to inhibit MAO-A in the brain of the subject.
  • administering to the brain of a subject a MAO-B inhibitor is an amount that is sufficient to inhibit MAO-A in the brain of the subject results in inhibition of both, MAO-A and MAO-B in the brain.
  • a method as described herein can be used for treating neuropsychiatric conditions such as depression, e.g., by means of inhibiting MAO-A in the brain.
  • a method as described herein can particularly be used for treating Parkinson's disease, and, in some embodiments, for treating motor symptoms and neuropsychiatric (e.g., depression) symptoms associated with Parkinson's disease in a subject in need thereof.
  • motor symptoms and neuropsychiatric e.g., depression
  • a "subject in need thereof is a subject suffering from a neuropsychiatric condition or symptom, such as depression.
  • the subject suffers from Parkinson's disease.
  • Such subjects are also referred to herein and in the art as “Parkinsonian" subjects or patients.
  • the subject is a Parkinsonian subject who suffers, in addition to motor symptoms associated with Parkinson's disease, from neuropsychiatric symptoms (e.g., depression) associated with Parkinson's disease.
  • neuropsychiatric symptoms e.g., depression
  • a method of treating motor and neuropsychiatric symptoms associated with Parkinson's disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of Rasagiline or a pharmaceutically acceptable salt thereof, wherein said administering is effected by intranasal administration.
  • neuropsychiatric conditions are conditions that result from imbalanced brain activity and include, for example, depression, psychosis, impulse control disorders, cognitive impairment, anxiety, dementia and sleep disturbances.
  • Neuropsychiatric symptoms result from a disease or disorder such as Parkinson's disease, and are used herein to define non-motor symptoms such as, for example, depression, drug-induced psychosis and impulse control disorders, cognitive impairment, anxiety, dementia and sleep disturbances, which may result for the disease's etiology and/or treatment.
  • depression is interchangeable to the term “depressive illness” and encompasses psychiatric (or mental) conditions known as major depressive disorder, major depression, clinical depression, or simply depression. Such conditions are characterized, for example, by episodes of all-encompassing low mood accompanied by low self-esteem and loss of interest or pleasure in normally enjoyable activities.
  • Depression, or depressive illness is characterized, for example, by the presence of some or all of following symptoms: (i) depressed mood most of the day, nearly every day, as indicated by either subjective report or observation made by others; (ii) markedly diminished interest or pleasure in all, or almost all, activities most of the day, nearly every day; (iii) significant weight loss when not dieting or weight gain, or decrease or increase in appetite nearly every day; (iv) insomnia or hypersomnia nearly every day; (v) psychomotor agitation or retardation nearly every day; (vi) fatigue or loss of energy nearly every day; (vii) feelings of worthlessness or excessive or inappropriate guilt nearly every day; (viii) diminished ability to think or concentrate, or indecisiveness, nearly every day; and (ix) recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt or a specific plan for committing suicide.
  • depression can be determined either behaviorally, according to the above-indicated symptoms, or by well-known tests, such as, but not limited to, according to DSM-IV diagnostic criteria.
  • treatment or alleviation of depression can be determined behaviorally, according to the above-indicated symptoms, or by well-known tests, such as, but not limited to, according to DSM-IV diagnostic criteria.
  • depression or “depressive illness” refers to both depression as a neuropsychiatric condition per se, and depression symptoms associated with Parkinson's disease.
  • motor symptoms associated with Parkinson's disease include, for example, bradykinesia, rigidity, tremor at rest and postural instability.
  • a method of treating Parkinson's disease in a subject in need thereof comprising administering to the brain of the subject a pharmaceutical composition comprising a MAO-B inhibitor (Rasagiline or a salt thereof).
  • a pharmaceutical composition comprising a MAO-B inhibitor (Rasagiline or a salt thereof).
  • a method of treating motor symptoms and neuropsychiatric symptoms e.g., depression
  • a pharmaceutical composition comprising a MAO-B inhibitor (Rasagiline or a salt thereof).
  • a method of treating a neuropsychiatric condition comprising administering to the brain of the subject a pharmaceutical composition comprising a MAO-B inhibitor (Rasagiline or a salt thereof).
  • a neuropsychiatric condition e.g., depression
  • a pharmaceutical composition comprising a MAO-B inhibitor (Rasagiline or a salt thereof).
  • the depression is associated with Parkinson's disease and the subject is a Parkinsonian subject, as defined herein.
  • the MAO-B inhibitor e.g., Rasagiline or a salt thereof
  • a pharmaceutical composition comprising the same, as described herein.
  • a MAO-B inhibitor Rosagiline or a salt thereof
  • a pharmaceutical composition for the treatment of Parkinson's disease in a subject in need thereof, the pharmaceutical composition being formulated for administration into the brain of the subject (e.g., intranasal administration).
  • a MAO-B inhibitor Rosagiline or a salt thereof
  • a pharmaceutical composition for the treatment of motor symptoms and neuropsychiatric symptoms, such as depression, associated with Parkinson's disease in a subject in need thereof, the pharmaceutical composition being formulated for administration into the brain of the subject (e.g., intranasal administration).
  • a MAO-B inhibitor Rosagiline or a salt thereof
  • a pharmaceutical composition for the treatment of a neuropsychiatric condition (e.g., depression) in a subject in need thereof, the pharmaceutical composition being formulated for administration into the brain of the subject (e.g., intranasal administration).
  • the neuropsychiatric condition is associated with Parkinson's disease and the subject is a Parkinsonian subject, as defined herein.
  • a pharmaceutical composition comprising a MAO-B inhibitor (Rasagiline or a salt thereof), for use in the treatment of Parkinson's disease in a subject in need thereof, the pharmaceutical composition being formulated for administration into the brain of the subject (e.g., intranasal administration).
  • a MAO-B inhibitor Rosagiline or a salt thereof
  • a pharmaceutical composition comprising a MAO-B inhibitor (Rasagiline or a salt thereof), for use in the treatment of motor symptoms and neuropsychiatric symptoms (e.g., depression) associated with Parkinson's disease in a subject in need thereof, the pharmaceutical composition being formulated for administration into the brain of the subject (e.g., intranasal administration).
  • a MAO-B inhibitor Rosagiline or a salt thereof
  • a pharmaceutical composition comprising a MAO-B inhibitor (Rasagiline or a salt thereof), for use in the treatment of a neuropsychiatric (e.g., depression) and/or neurodegenerative condition (e.g., Parkinson's disease) in a subject in need thereof, the pharmaceutical composition being formulated for administration into the brain of the subject (e.g., intranasal administration).
  • a neuropsychiatric e.g., depression
  • neurodegenerative condition e.g., Parkinson's disease
  • the neuropsychiatric and/or neurodegenerative condition is associated with Parkinson's disease and the subject is a Parkinsonian subject, as defined herein.
  • the MAO-B inhibitor (Rasagiline or a salt thereof) is used in an amount that is capable of treating or alleviating depression and/or depressive illness symptoms, or any other neuropsychiatric symptom condition as defined herein, and any combination thereof, including neuropsychiatry symptoms associated with Parkinson's disease.
  • the MAO-B inhibitor (Rasagiline or a salt thereof) is used in an amount that is sufficient to inhibit MAO-A inhibition in the brain of the subject.
  • the MAO-B inhibitor (Rasagiline or a salt thereof) is administered in a therapeutically effective amount, and the therapeutically effective amount is an amount sufficient to treat or alleviate a neuropsychiatric (e.g., depression and/or depressive illness) symptoms associated with Parkinson's disease.
  • a neuropsychiatric e.g., depression and/or depressive illness
  • the MAO-B inhibitor (Rasagiline or a salt thereof) is administered in a therapeutically effective amount, and the therapeutically effective amount is an amount sufficient to inhibit MAO-A in the brain of the subject.
  • the composition is used such that an amount of the MAO-B inhibitor (Rasagiline or a salt thereof) administered to the brain of the subject is a therapeutically effective amount as described herein.
  • the composition is used such that an amount of the MAO-B inhibitor (Rasagiline or a salt thereof) is sufficient to inhibit MAO-A in the brain of the subject.
  • the MAO-B inhibitor Rosagiline or a salt thereof
  • the composition comprises a therapeutically effective amount of the MAO-B inhibitor (Rasagiline or a salt thereof), as described herein.
  • the composition comprises an amount of the MAO-B inhibitor (Rasagiline or a salt thereof) which is sufficient to inhibit MAO-A in the brain of the subject.
  • the MAO-B inhibitor Rosagiline or a salt thereof
  • terapéuticaally effective amount it is generally meant herein an amount effective to treat, alleviate or ameliorate a disorder or a symptom, or prolong the survival of the subject being treated.
  • therapeutically effective amount describes an amount of a MAO-B inhibitor (Rasagiline or a salt thereof) which is sufficient to alleviate the neuropsychiatric symptom or condition.
  • a pharmaceutical composition comprising a MAO-B inhibitor (Rasagiline or a salt thereof) as described herein comprises an amount of the MAO-B inhibitor (Rasagiline or a salt thereof) which, when administered, inhibits MAO-A in the brain.
  • the amount is sufficient to inhibit at least 50 % of the activity of MAO-A in the brain and is some embodiments, the amount is sufficient to inhibit at least 60 5, at least 70 %, at least 80 % or at least 85 % of the activity of MAO- A in the brain of the subject, including higher inhibition values.
  • the pharmaceutical composition is used at doses and regimens which provide a therapeutically effective amount of the MAO-B inhibitor (Rasagiline or a salt thereof) in the brain of the subject, and in some embodiments, such a therapeutically effective amount causes inhibition of MAO-A in the brain, as is described herein.
  • the MAO-B inhibitor Rosagiline or a salt thereof
  • the therapeutically effective amount of the MAO-B inhibitor is such that inhibits MAO- A in the brain, and administering the composition does not cause "cheese reaction", as described herein.
  • administering the composition does not result in inhibition of systemic MAO-A (MAO-A in the periphery) or results in reduced inhibition of systemic MAO-A.
  • the composition is used such that inhibition of MAO-A in the brain is effected, yet, "cheese reaction" is not caused.
  • administering the composition does not result in inhibition of systemic MAO-A (MAO-A in the periphery) or results in reduced inhibition of systemic MAO-A.
  • MAO-B inhibitor Rosagiline or a salt thereof
  • intranasal administration allows using wide range of dosing, wherein high doses of the drug will inhibit MAO-A (and MAO-B) in the brain without potentiation of sympathetic cardiovascular activity, i.e., without the side effect resulting from MAO-A inhibition and produced by said MAO-B inhibitor (Rasagiline or a salt thereof) when administered at high doses to the periphery and ingested together with a high tyramine content food (e.g., "cheese reaction").
  • the amount of Rasagiline or a salt thereof is such that a ratio of the inhibition of an activity of brain MAO-A to inhibition of an activity of peripheral MAO-A is higher than 1.
  • such a ratio can be 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, or 2, and even higher.
  • Such a ratio means, for example, that when the Rasagiline or any other MAO- inhibitor is administered to the subject and exhibits, for example, inhibition of 50 % of the MAO-A activity in the brain, the inhibition of peripheral MAO-A is lower than 50 %, and can be, for example, 40 %, 30 %, 20 % and even lower. Similarly, for inhibition of 80 % of MAO-A activity in the brain, inhibition of peripheral MAO-A is lower than 80 %, or lower than 70 %, or lower than 40 %, or lower than 30 %.
  • the above-described ratio is higher than the same ratio when Rasagiline or a salt thereof is administered orally or intraperitoneally. In some embodiments, the ratio is higher by 10 5, 20%, 30 %, 40 %, 50 % and even more compared to the same ratio when oral or IP administration is effected.
  • the pharmaceutical composition and/or the mode of administration are configured such that the above-indicated amount of the MAO-B inhibitor (e.g., Rasagiline or a salt thereof) is present in a brain of a subject following the administration.
  • the MAO-B inhibitor e.g., Rasagiline or a salt thereof
  • composition and/or a mode of the intranasal administration are configured such that following the administration, an amount of rasagiline in the brain of the subject is such that inhibits at least 50 % or at least 80 % of an activity of MAO-A in the brain.
  • composition and/or a mode of the intranasal administration are configured such that following the administration, an amount of Rasagiline in the brain of the subject is such that a ratio of the inhibition of an activity of brain MAO-A to inhibition of an activity of peripheral MAO- A is higher than 1, as described herein.
  • the method and pharmaceutical composition as described herein result in inhibition of both MAO-B and MAO-A in the brain.
  • the concentration of the pharmaceutically active agent, i.e., the MAO-B inhibitor as defined herein (Rasagiline or a salt thereof), in a pharmaceutical composition is determined in accordance with the particular agent chosen; its efficacy; a comparison of its bioavailability by the particular mode of administration used, e.g., intranasal administration, and by other routes of administration, e.g., parenteral injection or oral administration; and the desired frequency of administration combined with the desired single dosage of the formulation.
  • Such pharmacological data can routinely be obtained by the skilled artisan from animal experiments, e.g., in terms of index values. Exemplary animal experiments are provided in the Examples section that follows.
  • the dosage administered, for example, to a particular Parkinsonian patient will depend on the state of that patient, and will be determined as deemed appropriate by the practitioner.
  • the pharmaceutical composition is formulated and used (administered to the brain at a certain regimen) so as to deliver to the brain a MAO-B inhibitor (Rasagiline or a salt thereof) as described herein in an amount as described herein.
  • a MAO-B inhibitor Rosagiline or a salt thereof
  • such an amount inhibits MAO-A in the brain and may optionally also inhibit MAO-B in the brain.
  • the pharmaceutical composition is formulated and used (administered to the brain at a certain regimen) so as to deliver to the brain a MAO-B inhibitor as described herein in an amount that does not substantially inhibit systemic MAO-A, namely, MAO-A present in the periphery, for example, in liver and small intestine.
  • any one of the compositions, uses and methods as described herein the MAO-B inhibitor used (or a composition comprising the MAO-B inhibitor) is administered intranasally and hence directly into the brain.
  • administration of MAO-B inhibitor or the brain bypasses the circulation and in particular the liver and small intestine thus avoiding the undesired side effect produced by inhibition of the MAO-A enzyme in these tissues.
  • Intranasal administration is a noninvasive means for targeting the brain by passing the BBB, minimizing systemic absorption, and limiting potential peripheral side effects. Intranasal administration allows the drug administered to travel through the roof of the nose, along the fibers of the olfactory and trigeminal nerves found in the mucosa of the nose, directly to the extracellular space of the neurons of the brain and spinal cord without having to cross the BBB or access the blood stream, and consequently, without exposing the other organs of the body to the drug, thus reducing its side effects and required dosage.
  • modes of administrations include, for example, local administration to the brain, for example, by intrastriatal administration, i.e., directly to the corpus striatum of the individual treated, ocular administration, and the like.
  • modes of administration typically utilize liquid compositions.
  • intranasal administration can be replaced by local, ocular or other modes for directly administering the MAO-B inhibitor to the brain.
  • Administration of the composition as described herein can be effected once daily, or twice daily, or once every two days. In some embodiments, administration is effected so as to maintain an amount of the MAO-B inhibitor (e.g., Rasagiline) in the brain of the subject, which inhibits MAO-A in the brain, as described herein.
  • the MAO-B inhibitor e.g., Rasagiline
  • a "pharmaceutical composition” refers to a preparation of an active compound (e.g., a MAO-B inhibitor such as Rasagiline or a salt thereof), with other chemical components such as pharmaceutically acceptable and suitable carriers and excipients.
  • an active compound e.g., a MAO-B inhibitor such as Rasagiline or a salt thereof
  • suitable carriers and excipients e.g., a pharmaceutically acceptable and suitable carriers and excipients.
  • the purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism, i.e., to the brain of the subject, as described herein.
  • the term "pharmaceutically acceptable carrier” refers to a carrier or a diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound.
  • carriers are: propylene glycol, saline, emulsions and mixtures of organic solvents with water, as well as solid (e.g., powdered) and gaseous carriers.
  • excipient refers to an inert substance added to a pharmaceutical composition to further facilitate administration of a compound.
  • excipients include calcium carbonate, calcium phosphate, various sugars (e.g., dextrose) and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.
  • the pharmaceutical composition is identified or indicated for administration once per day (e.g., as described herein).
  • the pharmaceutical composition comprises a unit dosage form, comprising a therapeutically effective amount of a MAO-B inhibitor, as described herein.
  • unit dosage form describes physically discrete units, each unit containing a predetermined quantity of MAO-B inhibitor calculated to produce the desired therapeutic effect, in association with at least one pharmaceutically acceptable carrier, diluent, excipient, or combination thereof.
  • the amount of MAO-B inhibitor in the unit dosage form may optionally be a daily dosage of the MAO-B inhibitor, as described herein, such that a method or treatment such as described herein may be effected by administration of one unit dosage form per day.
  • the amount of the MAO-B inhibitor in the unit dosage form may be, for example, half a daily dosage described herein, such that a method or treatment described herein may be effected by administration of two unit dosage forms per day; or a third or a quarter of a daily dosage described herein, such that a method or treatment described herein may be effected by administration of three or four unit dosage forms per day, respectively.
  • the pharmaceutical composition is formulated such that a single dosage of the composition contains a desired amount of the MAO-B inhibitor, as described herein, or can be formulated into a device or a delivery system that dispenses or releases a desired amount of the MAO-B inhibitor as described herein into the brain of a subject.
  • the pharmaceutical composition comprising the MAO-B inhibitor according to any one of the embodiments relating to the methods, uses and compositions, as described herein, can be prepared by conventional techniques, e.g., as described in Remington: The Science and Practice of Pharmacy, 19th Ed., 1995.
  • compositions of the present invention may be manufactured by processes well known in the art, e.g., by means of conventional mixing, dissolving, granulating, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.
  • compositions for use in accordance with the present invention thus may be formulated in conventional manner using one or more pharmaceutically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the MAO-B inhibitor (Rasagiline or a salt thereof) into preparations which can be used pharmaceutically and administered to the brain of a subject. Proper formulation is dependent upon the route of administration chosen.
  • compositions can be prepared, e.g., by uniformly and intimately bringing the active agent, i.e., a MAO-B inhibitor (Rasagiline or a salt thereof), as defined above, into association with a pharmaceutically acceptable carrier, such as a liquid carrier, a
  • the carrier is selected so as to reduce nasal absorption of the rasagiline, to thereby increase the amount of the drug that reaches the brain.
  • the composition may be in liquid, solid or semisolid form and may further include pharmaceutically acceptable fillers, carriers, diluents or adjuvants, and other inert ingredients and excipients.
  • the pharmaceutical composition of the present invention is formulated in a solid form, e.g., as a powder and/or as nanoparticles.
  • the powder formulation comprises, or consists of, a sugar, as described herein (e.g., dextrose, lactose, sucrose, mannitol, or sorbitol), as an acceptable carrier.
  • a sugar as described herein (e.g., dextrose, lactose, sucrose, mannitol, or sorbitol)
  • the pharmaceutical composition can be formulated for any suitable route of administration that may deliver the active agent directly into the brain, as described herein, and is preferably formulated for intranasal administration.
  • a pharmaceutical composition formulated for intranasal administration may be liquid, e.g., adapted for administration as a spray or drops.
  • Liquid preparations such as those based on aqueous formulations, may include ancillary agents, e.g., a pH-buffering system, for example, a buffer such as phosphate, borate, citrate or acetate buffers, a preservative, and an osmotic pressure controlling agent, e.g., glycerol or sodium chloride.
  • ancillary agents e.g., a pH-buffering system, for example, a buffer such as phosphate, borate, citrate or acetate buffers, a preservative, and an osmotic pressure controlling agent, e.g., glycerol or sodium chloride.
  • Non limiting examples of buffering agents/systems include boric acid, sodium bicarbonate, sodium citrate, sodium acetate, sodium phosphate monobasic, sodium phosphate dibasic, sodium phosphate dibasic heptahydrate, potassium dihydrogen phosphate, and combinations thereof such as combinations of boric acid and sodium bicarbonate, sodium phosphate monobasic and sodium phosphate dibasic, or sodium citrate and citric acid. If a buffering agent is employed, it is chosen in quantities that preferably do not irritate the nasal mucosa.
  • the carrier is an aqueous carrier, e.g., water.
  • aqueous carrier e.g., water.
  • Such preparations may be prepared by dispersing the active agent, i.e., the MAO-B inhibitor as defined herein (Rasagiline or a salt thereof), and ancillary agents, utilizing any method usually employed for suspension or emulsification, e.g., ultrasonic treatment. Adjustment of the aqueous phase to neutrality, i.e., to pH in the range from about 6.5 to about 8, may be accomplished in any of the preparatory steps.
  • microemulsions for intranasal administration are prepared in which the size of the dispersed particles or droplets is of the order of 10 nm, thereby facilitating their passage across the nasal mucosa.
  • Such microemulsions may be sterilized by filtration.
  • the pharmaceutical composition includes one or more agents that increase viscosity, chosen in quantities that preferably do not irritate the nasal mucosa and increase nasal retention time.
  • agents that increase viscosity include, without being limited to, methylcellulose, carboxymethylcellulose sodium, ethylcellulose, carrageenan, carbopol, and combinations thereof.
  • the pharmaceutical composition may contain aqueous diluents, e.g., saline, water, dextrose, and combinations thereof, and/or non-aqueous, e.g., alcohols, particularly polyhydroxy alcohols such as propylene glycol, polyethylene glycol, and glycerol, vegetable oils and mineral oils. These aqueous and non-aqueous diluents can be added in various concentrations and combinations to form solutions, suspensions, oil-in-water emulsions or water-in-oil emulsions.
  • the pH of the compositions may be adjusted to the desired value using any suitable organic or inorganic acid or organic or inorganic base.
  • suitable organic acids include, without limiting, acetic acid, citric acid, glutamic acid and methane sulfonic acid.
  • Suitable inorganic acids include, but are not limited to, hydrochloric acid and sulphuric acid.
  • Suitable organic bases include, without limiting, meglumine, lysine and tromethamine.
  • Suitable inorganic bases include, without being limited to, sodium hydroxide and potassium hydroxide.
  • Solvents that may be used to prepare the pharmaceutical compositions of the invention include, without being limited to, water, ethanol, propylene glycol, polyethylene glycol, glycerin, phenol, glycofurol, benzyl benzoate and polyoxyethylene castor oil derivatives.
  • the pharmaceutical composition is in a solid form, and comprises pharmaceutically acceptable solid carrier.
  • Suitable carriers and/or excipients include, for example, fillers such as sugars, including dextrose, lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose; and/or physiologically acceptable polymers such as polyvinylpyrrolidone (PVP).
  • PVP polyvinylpyrrolidone
  • disintegrating agents may be added, such as cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
  • the carrier includes sacchraride (sugar) as a filler, for example, dextrose, lactose, sucrose, mannitol, or sorbitol.
  • sacchraride sucrose
  • lactose sucrose
  • mannitol e.g., mannitol
  • sorbitol e.g., sorbitol
  • the MAO-B inhibitor can be conveniently delivered in the form of an aerosol spray presentation (which typically includes powdered, liquefied and/or gaseous carrier) from a pressurized pack or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane or carbon dioxide.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichloro-te
  • the dosage unit may be determined by providing a valve to deliver a metered amount.
  • Capsules and cartridges of, e.g., gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of MAO-B inhibitor (Rasagiline or a salt thereof) and a suitable powder base such as, but not limited to, lactose or starch.
  • compositions of the invention may contain excipients such as antioxidants, chemical preservatives, buffering agents, agents that increase viscosity, diluents, pH adjusters, and solvents.
  • Antioxidants are substances that prevent oxidation of the formulations.
  • Suitable antioxidants for use in the compositions of the invention include, without being limited to, butylated hydroxytoluene, butylated hydroxyanisole, potassium metabisulfite, and the like.
  • the pharmaceutical composition of the present embodiments contains a preservative chosen in quantities that preserve the composition but do not cause irritation of the nasal mucosa.
  • suitable preservatives include, without limiting, benzalkonium chloride, methyl, ethyl, propyl- or butylparaben, benzyl alcohol, phenylethyl alcohol, benzethonium, and combinations thereof.
  • compositions of the present embodiments may contain other pharmaceutically acceptable ingredients well known in the art.
  • excipients include, without limiting, chelating agents such as edetic acid or a salt thereof, flavors, sweeteners, thickening, adhesive or gelling agents, e.g., celluloses such as methylcellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, sodium carboxyl cellulose and microcrystalline cellulose, poloxomers, polyethylene glycols, carbomers or polyethylene oxide.
  • chelating agents such as edetic acid or a salt thereof
  • flavors sweeteners
  • thickening e.g., celluloses such as methylcellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, sodium carboxyl cellulose and microcrystalline cellulose, poloxomers, polyethylene glycols, carbomers or polyethylene oxide.
  • celluloses such as methylcellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, sodium carboxyl cellulose
  • the pharmaceutical composition and the device for dispensing it can be administered to a single nostril or to both nostrils. In some embodiments, it is administered to both nostrils.
  • a device configured for intranasal administration of a pharmaceutical composition comprising a MAO-B inhibitor (Rasagiline or a salt thereof) as described herein to a subject.
  • a MAO-B inhibitor Rosagiline or a salt thereof
  • the device is configured for dispensing the composition, from a container comprising the composition, and may comprise means for dispensing a pre-determined dose of the composition from the container and delivering said dose intranasally.
  • the pre-determined dose is such that when administered intranasally, results in an amount of the MAO-B inhibitor in the brain which is a therapeutically effective amount, as described herein, and/or is sufficient to inhibit MAO-A in the brain, as described herein.
  • a system for intranasal administration of Rasagiline or a pharmaceutically acceptable salt thereof as described herein comprises means for dispensing a pre-determined dose of Rasagiline or a salt thereof and for intranasally delivering the pre-determined dose, which is effective for alleviating neuropsychiatric and motor symptoms associated with Parkinson's disease, as described herein.
  • a system for intranasal administration of Rasagiline or a pharmaceutically acceptable salt thereof as described herein comprises means for dispensing a pre-determined dose of Rasagiline or said salt thereof and for intranasally delivering the pre-determined dose, which is g effective for treating neuropsychiatric and/or neurodegenerative conditions in a subject in need thereof, as described herein.
  • compositions may be administered as drops, sprays, aerosols or by any other intranasal dosage form or a dosage form for administering into the brain, as described herein.
  • the delivery system may be a unit dose delivery system.
  • the volume of solution, powder or suspension delivered per dose may be anywhere from 10 to 10000 ⁇ and preferably 1000-5000 ⁇ .
  • Delivery systems for these various dosage forms may be dropper bottles, plastic squeeze units, atomizers, nebulizers, metered nasal sprayers, metered-occular sprays, or pharmaceutical aerosols in either unit dose or multiple dose packages.
  • Aerosol systems require a propellant to be inert towards the formulation.
  • Suitable propellants may be selected among such gases as fluorocarbons, hydrocarbons, nitrogen and dinitrogen oxide or mixtures thereof.
  • the device is configured for dispensing a composition, as described herein, wherein the composition is a solid compotation (e.g., in a powder form).
  • the MAO-B inhibitor is Rasagiline (N-propargyl-l-(R)-aminoindan) or a salt thereof.
  • the MAO-B inhibitor is Rasagiline or a pharmaceutically acceptable salt thereof.
  • Non-limiting examples of pharmaceutically acceptable salts of Rasagiline include the mesylate salt; the esylate salt; the maleate salt; the fumarate salt; the tartrate salt; the sulfate salt; the hydrochloride salt; the hydro bromide salt; the p- toluenesulfonate salt; the benzoate salt; the acetate salt; or the phosphate salt of rasagiline.
  • compositions of rasagiline may be prepared according to any suitable technique known in the art, e.g., as described in detail in US 5,532,415.
  • the Rasagiline is used as a mesylate salt of Rasagiline.
  • the MAO-B inhibitor e.g., Rasagiline
  • the MAO-B inhibitor can be in any of the possible stereoisomers or enantiomers, or as a mixture of two or more stereoisomer sot enantiomers, or as a racemic mixture.
  • an amount of Rasagiline or a salt thereof administered to the brain of the subject is lower than an amount equivalent to 10 mk/kg per day in rats, that is, lower than the amount required for inhibiting MAO- A in the brain when Rasagiline or a salt thereof is administered orally or IP. In some of any the embodiments described herein, an amount of Rasagiline or a salt thereof administered to the brain of the subject is higher than an amount equivalent to 1 mg per day in humans.
  • An amount of 1 mg in humans is equivalent to about 0.1 mg/kg in rats.
  • the amount is higher than 2 mg, and in come embodiments, the amount is 1.1, 1.5,1.8, 2, 2.5, 3, 3.5, 4, 4.5, 5 or higher, including any intermediate value or subranges between said values.
  • an amount of Rasagiline or a salt thereof administered to the brain of the subject is higher than an amount equivalent to 0.1 mg/kg in rats, and can range, for example, from an amount equivalent to 0.2 mg/kg in rats to 6 mg/kg in rats, including any value and subrange therebetween.
  • MAO-B inhibitors such as selegiline (( ?)-N-methyl-N-(l-phenylpropan- 2-yl)prop-l-yn-3-amine; L-depreny; Eldepryl), and optionally safinamide (7V2- ⁇ 4-[(3- fluorobenzyl)oxy]benzyl ⁇ -L-alaninamide), or a pharmaceutically acceptable salt thereof, can be used instead of Rasagiline.
  • a methodology can be used for improving the ratio of inhibiting an activity of MAO-A such that inhibition of brain MAO-A is higher than inhibition of peripheral (e.g., liver and/or intestine) MAO-A, namely that the ratio between inhibition of brain and peripheral MAO-A is higher than 1.
  • Such an improvement when compared, for example, to the ratio obtained when Rasagiline or a salt thereof is administered orally or IP, is advantageous, for example, as it reduced the side effects associated with inhibiting peripheral MAO-A, yet allows to obtain higher amount of the drug in the brain and thus benefit from additional therapeutic effect such as alleviation or treatment of neuropsychiatric symptoms and/or conditions, as described herein.
  • Such a methodology can be used by mode of administrations other than intranasal administration, or any other administration to the brain, as described herein.
  • a method of treating a neuropsychiatric and/or neurodegenerative condition is a subject in need thereof, which comprises administering to the subject a therapeutically effective amount of Rasagiline or a pharmaceutically acceptable salt thereof, wherein administration is effected at a dose and/or a mode of administration selected such that a ratio of the inhibition of an activity of brain MAO -A to inhibition of an activity of peripheral MAO-A in the subject is higher than 1, as described in any one of the respective embodiments herein.
  • a system configured for administering Rasagiline or a pharmaceutically acceptable salt thereof to a subject in need thereof, the system comprising means for delivering Rasagiline or a salt thereof to the subject, wherein the means are such that upon delivering Rasagiline or said salt thereof, a ratio of the inhibition of an activity of brain MAO-A to inhibition of an activity of peripheral MAO-A in the subject is higher than 1, according to any one of the respective embodiments described herein.
  • Exemplary modes of administration and corresponding systems include, without limitation, transdermal administration, e.g., via a patch; topical administration; local administration to the brain by, e.g., injection or by guided therapy; and intranasal administration and corresponding systems as described herein.
  • any of the methods and systems and compositions as described herein can be utilized for improving the efficacy of Rasagiline or a salt thereof by means of activities exerted by its metabolites, particularly by the l-(R)-amino indan.
  • this metabolite may exhibit additional therapeutic effects such as neuroprotective and neurorestorative effects in the brain.
  • Using the compositions, methods and systems as described herein should result in enhanced concentration of this metabolite in the brain and thus by additional therapeutic effects of a composition comprising Rasagiline or a salt thereof, as described herein.
  • the methods, compositions and systems as described herein which account for a relatively high amount of Rasagiline in the brain, and hence, presumably for a relatively high amount of its metabolites in the brain, can be beneficially used for treating various neurodegenerative and neuropsychiatric conditions that can be treated by the aminoindan metabolite, and, for example, by its neuroprotective and neurorestorative effect. These conditions include any one of the conditions listed in the Examples section hereinbelow and those which have been previously described, including Parkinson's disease per se and a neuropsychiatric condition.
  • the MAO-B inhibitor can be used in combination with an additional active agent or drug, for example, an anti-Parkinsonian drug such as 1-DOPA.
  • compositions, method or structure may include additional ingredients, steps and/or parts, but only if the additional ingredients, steps and/or parts do not materially alter the basic and novel characteristics of the claimed composition, method or structure.
  • a compound or “at least one compound” may include a plurality of compounds, including mixtures thereof.
  • range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.
  • method refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the chemical, pharmacological, biological, biochemical and medical arts.
  • treating includes abrogating, substantially inhibiting, slowing or reversing the progression of a condition, substantially ameliorating clinical or aesthetical symptoms of a condition or substantially preventing the appearance of clinical or aesthetical symptoms of a condition.
  • Rasagiline (mesylate salt), was used.
  • Figure 1 demonstrates that rasagiline (0.3 mg/kg) significantly inhibited brain MAO-A inhibition by using NAS delivery compared to IP administration.
  • Figure 2 demonstrates that no significant difference in brain MAO-B inhibition is observed between the two modes of drug administration.
  • Figure 3 demonstrates that rasagiline (0.3 mg/kg) significantly inhibited liver MAO-A inhibition when administered IP, compared to NAS delivery. No significant differences in liver MAO-B inhibition were observed between the two modes of drug administration, as shown in Figure 4.
  • Rasagiline as a mesylate salt
  • a mesylate salt of Rasagiline was used in all experiments.
  • Powder formulation of rasagiline was prepared using a dextrose filler.
  • Liquid formulation of rasagiline was prepared in water as a vehicle. Control liquid formulations included vehicle only.
  • intranasal (I.N.) delivery of rasagiline in powder formulation at 0.6 mg/kg caused a significant higher inhibition of striatal MAO- A activity, compared to the same dose of rasagiline delivered in liquid formulation in rats.
  • intranasal (I.N.) treatments of giline (0.24, 0.6, 1.5 and 6 mg/kg) in powder formulation dose-dependently inhibited MAO-A activity in rat striatum and hippocampus, while more than 90 % MAO-A inhibition was observed at a dose of 6 mg/kg (in powder formulation).
  • Table 2 below presents the data obtained for MAO-B inhibition.
  • Rasagiline at doses ranging from 0.24 to 6 mg/kg
  • significantly inhibited about 98 %; p ⁇ 0.05
  • MAO-B activity in the striatum and hippocampus of drug-treated rats compared to respective vehicle-treated animals (not shown).
  • Table 3 below and Figure 7 present the ratio of MAO-A inhibition in the CNS vs. the periphery, represented by the ratio of MAO-A inhibition in striatum/ Hippocampus and intestines or striatum/Hippocampus and liver, upon intranasal (I.N.) delivery of rasagiline, at variables doses in powder formulation.
  • a dose of 0.6 mg/kg intranasally delivered Rasagiline resulted in the highest ratio of % MAO-A inhibition in the striatum vs. small intestine.
  • Liquid oral formulation of rasagiline was prepared in water as a vehicle.
  • Control liquid formulations included vehicle only.
  • Figures 8 A and 8B present the effects of acute intranasal delivery vs. oral administration of rasagiline on rat striatal and hippocampal MAO-A and MAO-B, respectively, and the ratio of striatal/small intestinal MAO-A inhibition, respectively.
  • Figure 9 presents the ratio of % MAO-A inhibition in the striatum/small intestine, and shows that Rasagiline exerted significantly lower MAO-A inhibition in the periphery (small intestine) following intranasal delivery, compared to P.O. administration.
  • the tail suspension test is one of the most widely used models for assessing antidepressant- like activity in mice, based on the fact that animals that are subjected to short-term, inescapable stress by being suspended by their tail, will develop an immobile posture [Cryan, et al. Neurosci Biobehav Rev, 2005. 29: 571-625].
  • the TST was assayed using Rasagiline (0.2 mg/kg) and its metabolite l-(R)-aminoindan (5 mg/kg), vs. control, and the results are presented in Figure 10. It is shown that the duration of immobility of vehicle-treated aged rats was higher than vehicle-treated young animals. It is further shown that both rasagiline and l-(R)-aminoindan reduced the duration of immobility of drug-treated aged rats, compared to vehicle-aged group.
  • Rats (Male Sprague-Dawley rats, purchased from Harlan, Jerusalem, Israel) were randomly divided into four groups (7-9 animals in each experimental group): groups 1-3 were administrated rasagiline intranasally (IN) at doses of 0.02, 0.2 and 2 mg/kg, respectively; groups 4-5 were administrated with rasagiline orally (PO) at doses of 0.2 and 2 mg/kg, respectively; groups 6-7 were administrated either saline for the IN regimen or highly purified water in oral regimen.
  • IN intranasally
  • PO rasagiline orally
  • IN rasagiline was administered in a powder formulation containing dextrose.
  • PO rasagiline was administered in a formulation containing water.
  • the concentrations of rasagiline were determined based on previous chronic oral treatment in rats [Youdim, et al., 2001, Br J Pharmacol.132(2):500-6].
  • the animals were sacrificed by decapitation, and striatum, hippocampus, cerebellum, liver and small intestine have been removed rapidly and frozen in liquid nitrogen for further analyses.
  • Figure 11A shows the effects of IN and oral rasagiline administration on exploration and anxiety behavior of rats, using the OFT.
  • the MAO-A inhibition ratios of striatum/intestine ( Figure 14A), hippocampus/intestine ( Figure 14B) and hippocampus/liver ( Figure 14D) were significantly higher following IN administration, compared to PO administration of rasagiline (0.2 mg/kg).
  • a dose of 0.2 mg/kg rasagiline, administered either IN or PO, resulted in almost complete inhibition of MAO-B in the striatum and hippocampus (> 85 %), as shown in Figure 14D.
  • Figures 15A-D show the data obtained in HPLC analysis of striatal dopamine (DA) and its metabolites following the above-indicated treatments.
  • DA striatal dopamine
  • Figure 15A shows the data obtained in HPLC analysis of striatal dopamine (DA) and its metabolites following the above-indicated treatments.
  • IN and PO treatment with rasagiline led to increased DA levels ( Figure 15A)
  • reduced levels of intraneuronal DA metabolites, 3,4- dihydroxyphenylacetic acid (DOPAC) see, Figure 15B
  • homovanillic acid (HVA) see, Figure 15C
  • 3-MT 3- methoxytyramine
  • DOPAC/DA see, Figure 16 A
  • HVA/DA see, Figure 16B
  • ratios were significantly decreased following IN, compared to PO, administration of rasagiline (0.2 mg/kg).
  • 3-MT/DA Catechol-O-methyltransferase (COMT)- associated methylation pathway
  • 3-MT/DOPAC DA reuptake index
  • FIGs 17A-D show data obtained for the level of serotonin and its metabolite, and of norepinephrin, following the above-indicated treatments.
  • the IN administration of rasagiline significantly and dose-dependently increased the levels of striatal serotonin (5-HT) (see, Figure 17A) and reduced the levels of 5-HT metabolite, 5-hydroxyindoleacetic (5-HIAA) (see, Figure 17B).
  • Striatal 5-HT levels were significantly higher in IN-treated rats with rasagiline (2 mg/kg), compared to PO-treated rats.
  • the 5-HIAA/5-HT ratio was significantly decreased following IN, compared to PO, administration of rasagiline (0.2 and 2 mg/kg) (see, Figure 17C).
  • IN administration of rasagiline (2 mg/kg) also resulted in increased norepinephrine (NE) levels, which were higher compared to PO administration (see, Figure 17D).
  • NE norepinephrine
  • Rasagiline and the tested filler were mechanical grounded and mixed well for homogenous powder purpose. Rasagiline concentrations in the formulations were adjusted according to each experiment.
  • the formulation was transferred into an Intra-nasal device as depicted in Figure 19. This device was found to be effective for IM administration of solid formulations to rats.
  • the powder is loaded where indicated by the arrow.
  • the syringe is filled with air, compressed to a volume of 5 ml of air pressure. After inserting the tip to rat nostril, the valve opens and releases the air. The powder is released with the air pressure.
  • Rasagiline was dissolved in Saline solution according to the tested concentrations. The solution has been introduced to the nostril rats with appropriate tip.
  • Figures 20A-B present the effect of the various powder formulations on striatal and hippocampal MAO-A activity. As shown therein, striatal and hippocampal MAO- A inhibition was significantly higher using dextrose as a filler in the powder IN formulation, compared to calcium carbonate and CMC.
  • striatal MAO-A inhibition was significantly higher using the powder I formulation, compared to the liquid formulation.
  • the MAO-A inhibition ratios of striatum/liver ( Figure 21B) and striatum/intestine ( Figure 21C) were also higher using the powder IN formulation, compared to the liquid IN formulation and to PO administration.
  • striatal MAO-B was almost completely inhibited by rasagiline (0.6 mg/kg), using the powder or liquid IN formulations. Intestinal MAO-B inhibition was similar in both IN formulations of rasagiline, and was significantly lower, compared to PO drug administration.
  • a dose-dependent effect of IN rasagiline in powder formulation on MAO-A inhibition was further tested, at drug concentrations of 0.24-6 mg/kg. Rats received vehicle (control) or various concentrations (0.24-6 mg/kg) of IN rasagiline in a powder formulation (dextrose). MAO-A activity was determined in striatum, hippocampus, liver and intestine.
  • MAO-A activity ratios of striatum/intestine and hippocampus/intestine were determined.

Abstract

Compositions, methods and devices for administration of Rasagiline or a pharmaceutically acceptable salt thereof are disclosed. The compositions, devices and methods can be utilized for treating conditions such as neuropsychiatric symptoms or conditions (e.g., depression), neurodegenerative conditions such as Parkinson's disease and/or motor and neuropsychiatric symptoms associated with Parkinson's disease.

Description

METHODS, COMPOSITIONS AND DEVICES FOR TREATMENT OF MOTOR AND DEPRESSION SYMPTOMS ASSOCIATED WITH PARKINSON'S DISEASE
FIELD AND BACKGROUND OF THE INVENTION
The present invention, in some embodiments thereof, relates to therapy and, more particularly, but not exclusively, to compositions, methods and devices useful for the treatment of neuropsychiatry conditions or symptoms such as depression and/or neurodegenerative conditions such as Parkinson's disease and/or motor and neuropsychiatric symptoms associated therewith.
Monoamine oxidase, also known as monoamine oxygen oxidoreductase, is abbreviated as MAO and has the EC NUMBER EC 1.4.3.4. This enzyme is known as oxidizing primary aliphatic and aromatic amines and some secondary and tertiary amines. The reaction catalyzed by MAO can be represented by the following generalized equation:
RCH2NR'R" + 02 + H20 RCHO + NR'R" + H202
Two isoenzymes of monoamine oxidase are present in most mammalian tissues. These isoenzymes, denoted in the art as MAO- A and MAO-B, were originally distinguished by their sensitivities to inhibition by the acetylenic inhibitors clorgyline and deprenyl and by their substrate specificities.
Typically MAO-A catalyzes the oxidative deamination of 5 -hydroxy tryptamine (5-HT), whereas MAO-B is active toward benzylamine and 2-phenylethylamine (PEA), yet, these substrate specificities are not absolute, and several studies have been conducted in the past years in this respect. See, for example, O'Carroll et al., in Biochemical Pharmacology, Vol. 38, No. 6, pp. 910-905, 1989; and Green et al., in Br. J. Pharmac, 1977, 60, 343-349.
In most species, tyramine and dopamine, as well as others, are substrates for both enzymes in the brain, and the role of MAO enzymes is recognized as regulating the metabolism of catecholamine neurotransmitters (e.g., dopamine and noradrenaline) and serotonin. A list of exemplary substrates of MAO-A and/or MAO-B is presented, for example, in Tipton et al., "Monoamine oxidase: functions in the central nervous system", In Encyclopedia of Neuroscience, Adelman, G; B. Smith, B, Eds:. Elsevier
Science BV, Amsterdam, 3rd Edition, 2004.].
MAO-A and/or MAO-B in peripheral tissues such as the intestine, liver, lung, and placenta appear to play a protective role in the body by oxidizing vasoactive amines from blood or preventing their entry into the circulation. In the central and peripheral nervous system, intraneuronal MAO-A and MAO-B have been suggested to protect neurons from exogenous amines and/or to regulate levels of neurotransmitter amines synthesized within a neuron.
As such, non selective MAO and selective MAO-A inhibitors were primarily considered as anti-depressants. Along the researches conducted, it was uncovered that more than 80 % inhibition of MAO-A is required for increasing the concentration of 5-
HT and noradrenaline in the brain and thus to exhibit antidepressant effects [See, for example, Tipton et al., 2004, supra].
However, the use of MAO-A selective or nonselective irreversible MAO inhibitors has been limited because individuals taking these drugs become susceptible to amines, such as tyramine, in the diet. These amines are normally degraded by MAO in peripheral tissues. When MAO is inhibited, ingested tyramine can enter the blood, from which it is taken up by adrenergic nerve terminals releasing stored noradrenaline and resulting in a hypertensive response (hypertensive crises). On the basis of the high concentrations of tyramine in some cheeses, this hypertensive response to dietary amines is widely known as the "cheese reaction" or "cheese effect". Tyramine is found in high concentration also in other food nutrients.
Longer-term administration of such inhibitors can lead to hypotension, possibly as a result of the accumulation of false transmitters in the nerves.
Thus, due to side effects of the MAO-A inhibitory drugs, e.g., hypertension
("cheese effect"), these drugs are often replaced by other antidepressants [Youdim et al.,
Journal of neural transmission, 1987, 25, 27-33; Youdim, Journal of neural transmission, 1980, 16, 157-161].
Most studies have shown that selective MAO-B inhibitors such as (-)-deprenyl (Selegiline) exhibit no effect in patients suffering from endogenous depression, and further have a very low interaction with tyramine when given either orally or intravenously. On the other hand, MAO inhibitors were found to be highly potent protectors against MPTP (l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine) neurotoxicity, which gives rise to a condition resembling idiopathic Parkinson's disease. Inhibitors of MAO are therefore considered to prolong the actions of dopamine in Parkinson's disease.
Parkinson's disease (PD) is a slowly progressive neurodegenerative disorder. It is characterized by motor symptoms, such as bradykinesia, rigidity, tremor at rest and postural instability, which are associated with degeneration of the nigrostriatal dopaminergic projection originating in the substantia nigra (SN). In addition to these motor symptoms, non-motor symptoms, such as olfactory dysfunction, can be observed even prior to the manifestation of motor symptoms in PD patients.
Depression is a common psychiatric comorbidity in PD, affecting more than 60 % of the patients. Pharmacotherapy for depression in PD entails special concerns related to different side effects of the various anti-depressants and great potential for drug-drug interaction. Selective serotonin reuptake inhibitors (SSRIs) are typically prescribed, however with often insufficient results.
Selegiline (also referred to in the art as Anipryl, (-)-deprenyl, L-deprenyl, Eldepryl, Emsam, Zelapar) and Rasagiline (N-propargyl-l-(R)-aminoindan; Marketed as Azilect®)) are dose-dependent selective irreversible inhibitors of MAO-B. As such they have found therapeutic applications for the treatment of Parkinson's disease (PD) and in the treatment of Major Depressive Disorder (MDD). Both drugs are orally- administered drugs, and are subject to extensive first pass hepatic metabolism, resulting in poor and highly variable oral bioavailability (35 % for Rasagiline and 4-10 % for Selegiline).
Although Rasagiline and Selegiline are preferential MAO-B inhibitors, their selectivity is dose-dependent; While Selegiline is approved for the treatment of depression, the dose is 3- to 6-fold higher than that for the treatment of PD, causing loss of MAO-B selectivity and requiring precautions to prevent hypertensive crises due to "cheese reaction".
Rasagiline is a new MAO-B inhibitor, introduced in 2006, that has 3- to 16-fold greater potency than Selegiline. Similarly to Selegiline, Rasagiline is generally devoid of potential to cause hypertensive crises, the "cheese reaction", unless administered at high concentrations that are sufficient to inhibit MAO-A [Youdim and Bakhle, 2006, Br J Pharmacol., 2006, 147 Suppl 1, S287-296].
Animal studies in rats showed that Rasagiline does not potentiate pressor responses to oral tyramine by single oral doses up to 5 mg/kg, or following 21 days of chronic treatment at oral doses up to 2 mg/kg daily. At 10 mg/kg oral dose of rasagiline, both MAO-A and MAO-B in rats are inhibited, and the irreversible inhibition of MAO-A induces the "cheese reaction" [Finberg et al., Selective irreversible propargyl derivative inhibitors of monoamine oxidase (MAO) without the cheese effect. In: Monoamine oxidase inhibitors - the state of the art. Youdim, M.B.H.; Peykel, E.S., eds. Chichester: Wiley; 1981a, 31-41; Finberg et al., Br J Pharmacol., 1981, 73, 65-74; Finberg and Youdim, Journal of Neural Transmission, 1988, Supplementum 26, 11-16; and Youdim, M.B.H., Expert Review of Neurotherapeutics, 2003, 3, 737-749].
The recommended dose of rasagiline for humans is 1 mg once daily when used alone (monotherapy), and 0.5-1 mg once daily when combined with 1-DOPA. Patients with mild liver disease should not use more than 0.5 mg daily.
Further, patients administered with Rasagiline are typically cautioned to avoid tyramine rich food, as well as administration of anti-depressants of the selective serotonin uptake inhibitors family, serotonin-norepinephrine uptake inhibitors family and other MAO inhibitors.
Rasagiline is primarily metabolized by hepatic cytochrome P-450 to form its major metabolite, l-(R)-aminoindan, a non-amphetamine, weak reversible MAO-B inhibitor compound. Recent studies indicated the potential neuroprotective effect of 1- (R)-aminoindan, suggesting that it may contribute to the overall neuroprotective and antiapoptotic effects of its parent compound, rasagiline. In contrast, one of the Selegiline principal metabolites is 1-methamphetamine which can be converted to 1- amphetamine. See, for example, Bar Am et al., Journal of Neurochemistry, 2010, Vol. 11, pp. 1131-1137; Weinreb et al, Antioxidants & Redox Signaling, Volume 14, Number 5, 2011, page 767.
There are several reports on administration of Rasagiline and/or Selegiline via routes other than the oral. These include, for example, Kalaria et al. [International Journal of Pharmaceutics 438 (2012) 202- 208], which describe gel patches for transdermal delivery of Rasagiline and Selegiline; and Ravi et al, 2013 Drug Delivery: Pages 1-8 November 29, 2013. which describe Intranasal thermosensitive gel for rasagiline mesylate (RM) delivery, which is reported to exhibit improved bioavailability over oral solutions.
Intranasal administration is a noninvasive means for targeting the brain bypassing the blood-brain barrier (BBB), minimizing systemic absorption, and limiting potential peripheral side effects [Vyas et al., Current drug delivery, 2005, 2, 165-175; Ilium, 2004, The Journal of pharmacy and pharmacology, 2004, 56, 3-17].
Additional background art includes deMarcaida et al. Mov Disord, 2006, 21, 1716-1721; Goren et al., Clin Pharmacol, 2010, 50, 1420-1428; Tipton et al., Biochemical Pharmacology, 1982, 31, 1251-1255; Ravaris et al., Arch Gen Psychiatry, Vol. 33, March 1976; U.S. Patent Application having Publication No. 2010/0189791; and U.S. Patent Nos. 5,453,446 and 5,668,181. SUMMARY OF THE INVENTION
While MAO-B inhibitors such as Rasagiline are useful in the treatment of Parkinson's disease, particularly in alleviating motor symptoms associated with Parkinson's disease, a need still remains to treat depression symptoms associated with this disease. Such a need becomes even more pronounced due to adverse drug-drug interactions between Rasagiline and commonly used anti-depressants such as SSRIs, and while considering the depression symptoms associated with a majority of Parkinsonian patients.
While MAO-B inhibitors such as, for example, Rasagiline and Selegiline, may act also as anti-depressants at higher doses, due to MAO-A inhibition, administration of these drugs at doses effective in treating MAO-A inhibition is limited by the "cheese reaction" (hypertensive crisis) associated with such high doses.
Currently, Rasagiline and Selegiline are prescribed for the treatment of Parkinson's disease at doses which are selective to MAO-B inhibition and are therefore ineffective in treating depression symptoms in Parkinsonian patients.
The present inventors have now designed and successfully practiced a novel methodology, in which a MAO-B inhibitor such as Rasagiline is administered into the brain at a range of doses, which are capable of treating neuropsychiatric conditions such as depression and/or alleviating neuropsychiatric (e.g., depression) symptoms (e.g., symptoms associated with Parkinson's disease). According to this methodology, administering a MAO-B inhibitor such as Rasagiline to the brain of a subject results in alleviating or treating both motor and depression symptoms associated with Parkinson's disease. This methodology, for example, is effected while utilizing Rasagiline or any other MAO-B inhibitor, at doses sufficient to inhibit MAO-A in the brain, possibly without potentiation of sympathetic cardiovascular activity (e.g., "cheese reaction"). Such a methodology allows using drugs such as Rasagiline for exhibiting antidepressant activity (e.g., due to MAO-A inhibition), and particularly, for exhibiting a dual effect of MAO-A and MAO-B inhibition, thereby improving the effect of the drug in patients suffering from Parkinson's disease by alleviating both motor and depression symptoms associated with the disease.
The present inventors have demonstrated that intranasal administration of Rasagiline at a range of doses, results in both MAO-A and MAO-B inhibition in the brain, whereby similar doses, when administered intraperitoneally (IP) or orally, are inefficient in inhibiting MAO-A in the brain. The present inventors have further demonstrated that intranasal administration of Rasagiline at a range of doses, results in efficient inhibition of MAO-A and MAO-B in the brain, yet in inefficient inhibition of MAO-A in the periphery (e.g., liver and small intestine). The methodology described herein can therefore be utilized optionally for administering to a subject in need thereof a therapeutically effective amount of a MAO-B inhibitor such as Rasagiline such that a ratio between inhibition of MAO-A in the brain and inhibition of MAO-A in the periphery is higher than the respective ratio that is obtained by oral administration of Rasagiline.
The methodology described herein therefore provides for a triple effect: treating motor disorders or symptoms, such as symptoms associated with Parkinson's disease, treating a neuropsychiatric condition such as depression, for example, depression symptoms associated with Parkinson's disease, and obviating the "cheese effect" which is otherwise associated with administration of MAO-A inhibitors.
According to an aspect of some embodiments of the present invention there is provided a method of treating motor and neuropsychiatric symptoms associated with Parkinson's disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of Rasagiline or a pharmaceutically acceptable salt thereof, wherein the administering is effected by intranasal administration.
According to an aspect of some embodiments of the present invention there is provided a method of treating a neuropsychiatric condition such as depression in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of Rasagiline or a pharmaceutically acceptable salt thereof, wherein the administering is effected by intranasal administration.
According to some embodiments of the present invention, the depression is associated with Parkinson's disease.
According to an aspect of some embodiments of the present invention there is provided a method of treating a neuropsychiatric condition and/or a neurodegenerative condition in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of Rasagiline or a pharmaceutically acceptable salt thereof, wherein the administering is effected by intranasal administration.
According to some embodiments of the present invention, the condition is treatable by l-(R)-aminoindan.
According to some embodiments of the present invention, the amount of Rasagiline or a salt thereof is such that inhibits at least 50 % of an activity of MAO-A in the brain of the subject.
According to some embodiments of the present invention, the amount of Rasagiline or a salt thereof is such that inhibits at least 80 % of an activity of MAO-A in the brain of the subject.
According to some embodiments of the present invention, the amount of
Rasagiline or a salt thereof is such that a ratio of the inhibition of an activity of brain MAO-A to inhibition of an activity of peripheral MAO-A is higher than 1.
According to some embodiments of the present invention, the Rasagiline or a salt thereof is administered as a pharmaceutical composition which further comprises a pharmaceutically acceptable carrier. According to some embodiments of the present invention, the composition is in a form of a powder.
According to some embodiments of the present invention, the composition and/or a mode of the intranasal administration are configured such that following the administering, an amount of rasagiline in the brain of the subject is such that inhibits at least 50 % or at least 80 % of an activity of MAO-A in the brain.
According to some embodiments of the present invention, the composition and/or a mode of the intranasal administration are configured such that following the administering, an amount of rasagiline in the brain of the subject is such that a ratio of the inhibition of an activity of brain MAO-A to inhibition of an activity of peripheral MAO-A is higher than 1.
According to some embodiments of the present invention, the amount of rasagiline or a salt thereof is equivalent to an amount that ranges from 0.2 mg/kg per day to 6 mg/kg per day in rats.
According to some embodiments of the present invention, the subject is a human and the amount of rasagiline or a salt thereof is higher than 2 mg per day.
According to an aspect of some embodiments of the present invention there is provided a pharmaceutical composition comprising Rasagiline or a pharmaceutically acceptable salt thereof, the composition being formulated for intranasal administration.
According to some embodiments of the present invention, the composition is in a form of a powder.
According to some embodiments, the composition is identified for use in treating or alleviating any one of the conditions and/or symptoms as described herein.
According to an aspect of some embodiments of the present invention there is provided a use of Rasagiline or a pharmaceutically acceptable salt thereof in the manufacture of a pharmaceutical composition (medicament) for treating or alleviating any one of the conditions and/or symptoms as described herein.
According to an aspect of some embodiments of the present invention there is provided a system for intranasal administration of Rasagiline or a pharmaceutically acceptable salt thereof to a subject in need thereof, the system comprising means for dispensing a pre-determined dose of Rasagiline or the salt thereof and for intranasally delivering the dose, the pre-determined dose being effective for alleviating neuropsychiatric and motor symptoms associated with Parkinson's disease.
According to an aspect of some embodiments of the present invention there is provided a system for intranasal administration of Rasagiline or a pharmaceutically acceptable salt thereof to a subject in need thereof, the system comprising means for dispensing a pre-determined dose of Rasagiline or the salt thereof and for intranasally delivering the dose, the pre-determined dose being effective for treating neuropsychiatric and/or neurodegenerative conditions in a subject in need thereof, as described herein (e.g., depression).
According to some embodiments of the present invention, the pre-determined dose is effective for treating depression.
According to an aspect of some embodiments of the present invention there is provided a method of treating a neuropsychiatric and/or neurodegenerative condition in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of Rasagiline or a pharmaceutically acceptable salt thereof, wherein the administering is effected at a dose and/or a mode of administration selected such that a ratio of the inhibition of an activity of brain MAO-A to inhibition of an activity of peripheral MAO-A in the subject is higher than 1.
According to an aspect of some embodiments of the present invention there is provided a system configured for administering Rasagiline or a pharmaceutically acceptable salt thereof to a subject in need thereof, the system comprising means for delivering Rasagiline or the salt thereof to the subject, wherein the means are such that upon delivering Rasagiline or the salt thereof, a ratio of the inhibition of an activity of brain MAO-A to inhibition of an activity of peripheral MAO-A in the subject is higher than 1.
According to some embodiments of the present invention, the method and system are for use in treating or alleviating any one of the conditions and/or symptoms described herein.
Unless otherwise defined, all technical and/or scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the invention, exemplary methods and/or materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be necessarily limiting. BRIEF DESCRIPTION OF THE SEVERAL VIEW OF THE DRAWINGS
Some embodiments of the invention are herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of embodiments of the invention. In this regard, the description taken with the drawings makes apparent to those skilled in the art how embodiments of the invention may be practiced.
In the drawings:
FIG. 1 is a bar graph showing brain MAO-A inhibition by rasagiline (0.1 mg/kg and 0.3 mg/kg) administered intraperitonealy (IP) and intranasally (NAS;) to adult male Sprague Dawley rats (*p<0.05 vs. vehicle treated rats, one way ANOVA with Dunnett post test, n=4).
FIG. 2 is a bar graph showing brain MAO-B inhibition by rasagiline (0.1 mg/kg and 0.3 mg/kg) administered IP and NAS to adult male Sprague Dawley rats **p<0.01 vs. vehicle treated rats, one way ANOVA with Dunnett post test, n=4).
FIG. 3 is a bar graph showing liver MAO-A inhibition by rasagiline (0.1 mg/kg and 0.3 mg/kg) administered IP and NAS to adult male Sprague Dawley rats (*p<0.05 vs. vehicle treated rats, one way ANOVA with Dunnett post test, n=4).
FIG. 4 is a bar graph showing liver MAO-B inhibition by rasagiline (0.1 mg/kg and 0.3 mg/kg) were administered IP and NAS to adult male Sprague Dawley rats **p<0.01 vs. vehicle treated rats, one way ANOVA with Dunnett post test, n=4).
FIG. 5 is a bar graph showing striatal MAO-A inhibition by intranasal delivery of rasagiline, given in powder or liquid formulation to acute-treated adult male Sprague Dawley rats. Rats were administered intranasally with rasagiline in dextrose powder formulation (0.6 and 6 mg/kg; 5-ml puff), liquid formulation (0.6 and 6 mg/kg) or respective vehicle (control). Results are represented as mean (% of control) + SEM (n= 9- 10 animals per group). *** p<0.001 powder vs. liquid delivery. FIG. 6 is a bar graph showing a dose-depending effect of intranasal delivery of rasagiline, given in powder formulation, on MAO-A activity in striatum and hippocampus in acute-treated adult male Sprague Dawley rats. Rats were administered intranasally with either vehicle or rasagiline in dextrose powder formulation (0.24, 0.6, 1.5 and 6 mg/kg; 5-ml puff). Results are represented as mean (% of control) + SEM (n= 9-10 animals per group). *** p<0.05 vs. controls.
FIG. 7 is a bar graph showing the effect of intranasal administration of rasagiline, given in liquid or powder formulations, on the ratio of striatal/small intestinal MAO-A inhibition in acute-treated adult male Sprague Dawley rats. Rats were intranasally administered either with rasagiline in dextrose powder formulation (0.24,
0.6, 1.5 and 6 mg/kg; 5-ml puff), liquid formulation (0.6 and 6 mg/kg), or respective vehicle (control). Results are represented as the ratio of % of MAO-A inhibition in rat striatum/small intestine; mean + SEM (n= 9-10 animals per group). * p<0.05 powder vs. liquid intranasal delivery.
FIGs. 8A-B are bar graphs showing the effect of intranasal and oral administration of Rasagiline on MAO-A activity in striatum (FIG. 8A) and hippocampus FIG. 8(B) in acute-treated adult male Sprague Dawley rats. Rats were administered either intranasally (IN, dextrose powder formulation, 5-ml puff) or per-os (P.O) with rasagiline or respective vehicle (control). Results are represented as % of MAO-A inhibition of the respective control groups, mean + SEM (n= 9-10 animals per group). *** p<0.001, * p<0.05 I.N vs. P.O delivery.
FIG. 9 is a bar graph showing the effect of intranasal and oral administration of Rasagiline on the ratio of striatal/small intestinal MAO-A inhibition in acute-treated adult male Sprague Dawley rats. Rats were administered either intranasally (I.N, dextrose powder formulation, 5-ml puff) or per-os (P.O) with rasagiline, or respective vehicle (control). Results are represented as the ratio of % of MAO-A inhibition in rat striatum/small intestine; mean + SEM (n= 9-10 animals per group). **p<0.01, * p<0.05
1. N vs. P.O delivery.
FIG. 10 is a bar graph showing the effects of rasagiline (0.2 mg/kg) and 1-(R)- aminoindan (5 mg/kg) on immobility time of aged rats. Each bar represents the mean +SEM (n= 7-10 animals in each group). # p<0.05 vs. vehicle-treated young mice; * p<0.05 vs. vehicle-treated aged mice. FIGs. 11A-B are bar graphs showing the effect of I.N and P.O administration of rasagiline on time in center and distance in OFT. Rats received vehicle (control) or rasagiline, either IN or PO for 3 times a week, for 4 weeks. FIG. 11 A presents the time spending in the center (% of total time of examination) and FIG. 11B presents the total distance (m) analyzed in OFT. Values are expressed as the mean +SEM (n=7-9). *p<0.05 vs. respective controls; #p<0.05 vs. P.O-treated rats.
FIG. 12 is a bar graph showing the effect of IN and PO administration of rasagiline on the duration of immobility in FST. Rats received vehicle (control) or rasagiline, either IN or PO, for 3 times a week, for 4 weeks. The immobility time (% of total time of examination) was analyzed in FST. Values are expressed as the mean +SEM (n=7-9). *p<0.05 vs. respective control; #p<0.05 vs. P.O-treated rats.
FIGs. 13A-D are bar graphs showing the effect of IN and PO administration of rasagiline on MAO activity in the striatum (FIG. 13A), the hippocampus (FIG. 13B), the liver (FIG. 13C) and the intestine (FIG. 13D. Results are expressed as % inhibition of control and represent the mean + SEM (n=7-9). *p<0.05 vs. respective control; #p<0.05 vs. P.O-treated rats.
FIGs. 14A-D are bar graphs showing the effect of chronic IN and PO administration of rasagiline on MAO-A activity ratio of the following brain and peripheral tissues: striatum/intestine (FIG. 14A), hippocampus/intestine (FIG. 14B), striatum/liver (FIG. 14C) and hippocampus/liver (FIG. 14D). Values are expressed as the mean + SEM (n=7-9). *p<0.05 vs. respective control; #p<0.05 vs. P.O-treated rats.
FIGs. 15A-D are bar graphs showing the effect of IN and PO administration of rasagiline on striatal levels of DA (FIG. 15 A) and of its metabolites DOPAC (FIG. 15B), HVA (FIG. 15C) and 3-MT (FIG. 15D), as determined using HPLC analysis. Results represent mean + SEM (n=7-9). *p<0.05 vs. respective control; #p<0.05 vs. P.O-treated rats.
FIGs. 16A-D are bar graphs showing the effect of IN and PO administration of rasagiline on striatal DA metabolism expressed as the ratios of DOPAC/DA (FIG. 16A), HVA/DA (FIG. 16B) and 3-MT/DA (FIG. 16C). The DA reuptake index was expressed as 3-MT/DOPAC (FIG. 16D). Results represent mean + SEM (n=7-9). *p<0.05 vs. respective control; #p<0.05 vs. P.O-treated rats. FIGs. 17A-D are bar graphs showing the effect of IN and PO administration of rasagiline on striatal levels of 5-HT (FIG. 17A), its metabolite 5-HIAA (FIG. 17B), and of NE (FIG. 17D), as determined by HPLC analysis. FIG. 17C present the 5-HT metabolism was expressed as the ratio and 5-HIAA/5-HT. Results represent mean + SEM (n=7-9). *p<0.05 vs. respective control; #p<0.05 vs. P.O-treated rats.
FIGs. 18A-D are bar graphs showing the effect of IN and PO administration of rasagiline on hippocampal levels of 5-HT (FIG. 18A), its metabolite 5-HIAA (FIG. 18B) and of NE (FIG. 18D), as determined by HPLC analysis. FIG. 18C presents the 5- HT metabolism expressed as the ratio and 5-HIAA/5-HT. Results represent mean + SEM (n=7-9). *p<0.05 vs. respective control; #p<0.05 vs. P.O-treated rats.
FIG. 19 presents an image of an exemplary intranasal device useful for IN administration of a powder formulation to rats.
FIGs. 20A-B are bar graphs showing the effect of various IN rasagiline powder formulations on MAO-A activity in striatum (FIG. 20A) and hippocampus (FIG. 20B). Results represent as % of respective vehicles (mean + SEM, n=7-9). *p<0.05 vs. rasagiline+dextrose. CMC = carboxy methyl cellulose.
FIGs. 21A-C are bar graphs presenting the effect of IN rasagiline formulations, powder and liquid, and PO administration, on striatal MAO-A activity (FIG. 21A) and MAO-A inhibition ratios of striatum/liver (FIG. 21B) and striatum/intestine (FIG. 21C).
FIGs. 22A-D are bar graphs showing the effect of IN powder administration of rasagiline on MAO-A activity in striatum (FIG. 22A), hippocampus (FIG. 22C), liver (FIG. 22C) and intestine (FIG. 22D). Results represent mean + SEM (n=7-9). *p<0.05 vs. control.
FIG. 23 is a bar graph showing the effect of single and two nostrils IN administration of rasagiline (powder formulation) on MAO-A activity ratios: striatum/intestine and hippocampus/intestine. Results represent mean + SEM (n=7-9). * p<0.05 vs. single nostril administration.
DESCRIPTION OF SPECIFIC EMBODIMENTS OF THE INVENTION
The present invention, in some embodiments thereof, relates to therapy and, more particularly, but not exclusively, to compositions, methods and devices useful for the treatment of neuropsychiatry conditions or symptoms such as depression and/or neurodegenerative conditions such as Parkinson' s disease and/or motor and neuropsychiatric symptoms associated therewith.
Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not necessarily limited in its application to the details set forth in the following description or exemplified by the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways.
Parkinson's disease is the second most common neurodegenerative disorder, affecting 1-3 percent of people older than 50 years. Parkinson's disease is characterized by motor symptoms, such as bradykinesia, rigidity, tremor at rest and postural instability, which are associated with degeneration of the nigrostriatal dopaminergic projection.
Depression is a common and potentially debilitating aspect of Parkinson's disease, affecting 50-70 percent of Parkinsonian patients. Depression in Parkinson's disease is demonstrably different from ordinary major depression in terms of gender ratio, age, symptom profile, comorbidity, and chronicity. Treatment of depression in Parkinson's disease entails special concerns related to side effects and drug-drug interactions.
The currently most common drugs for the treatment of Parkinson' s disease are the irreversible selective MAO-B inhibitors (e.g., Rasagiline and Selegiline). These drugs are assumed to exert their primary effect in Parkinson' s disease (PD) by MAO-B inhibition which results in a slower metabolism of endogenous and exogenous dopamine (DA), thus providing symptomatic benefits (Finberg et al. 1996, 1998, supra).
Irreversible nonselective MAO-AB and selective MAO-A inhibitors are known as anti-depressants. Such drugs can potentiate the cardiovascular effect of the sympathomimetic amine, tyramine, present in many foods. Since tyramine is metabolized by MAO, the inhibition of MAO-A results in uptake of tyramine from circulatory system, which results in hypertensive crisis, known as the "cheese effect", as a consequence of noradrenaline release from peripheral adrenergic neurons by tyramine.
Rasagiline and Selegiline, which are currently used in the treatment of
Parkinson' s disease at doses in which MAO-B inhibition is exerted, may also exhibit MAO-A inhibition, however, at doses which are at least 3-fold higher that those required for exhibiting MAO-B inhibition.
Rasagiline, when given orally or IP, does not cause a "cheese reaction" at its selective MAO-B inhibitory activity dosage. However, at higher dosage it loses its selectivity and consequently further inhibits MAO-A, thus causing a "cheese reaction". Rasagiline is also contraindicated with several families of anti-depressants, including for example, the SSRIs. Thus, while treatment of Parkinsonian patients with Rasagiline results in alleviation of motor symptoms associated with the dopaminergic system, such a treatment limits the possibilities of alleviating depression symptoms associated with Parkinson's disease.
In a search for improving the current methodologies of treating Parkinson's disease, the present inventors have conceived administering a MAO-B inhibitor such as Rasagiline directly into the brain, at a dose that would affect depression in a subject in need thereof, and hence would affect both motor and depression symptoms associated with Parkinson's disease. The present inventors have envisioned administering a MAO- B inhibitor such as rasagiline at a dose which would inhibit both MAO-A and MAO-B in the brain, yet would not inhibit systemic (peripheral) MAO-A. Such a methodology provides for an efficient treatment of depression and particularly, for an efficient treatment of both motor symptoms and depression symptoms associated with Parkinson's disease, presumably due to MAO-A and MAO-B inhibition in the brain, and avoids inhibition of MAO-A in the periphery and the consequent adverse "cheese reaction".
As demonstrated in the Examples section that follows, the present inventors have uncovered that intranasal delivery of rasagiline in e.g., a powder formulation, resulted in inhibition of monoamine oxidase (MAO)-A, in rat striatum and hippocampus, following acute treatment. A powder formulation was shown to exhibit a greater efficacy compared to a liquid formulation. The intranasal delivery of rasagiline (0.6 mg/kg in rats) in powder formulation showed a significantly low peripheral MAO- A inhibition (expressed as the striatum/intestine MAO-A inhibitory ratio).
The present inventors have further uncovered that intranasal delivery of rasagiline in powder formulation (e.g., 0.24-6 mg/kg in rats) resulted in a dose- dependent MAO-A inhibition in the striatum and hippocampus (up to about 97 % and about 95 %, respectively) in rats. MAO-B was almost completely inhibited (about 98%) in the striatum and hippocampus, at all rasagiline doses analyzed.
The present inventors have further uncovered that intranasal delivery of rasagiline in a powder formulation (e.g., 0.24 and 0.6 mg/kg in rats) exerted significantly enhanced MAO-A inhibition in both the striatum and hippocampus, as compared to oral administration of rasagiline in acute-treated rats. Rasagiline at both regimens significantly inhibited (about 98%) MAO-B activity in the striatum and hippocampus of acute-treated rats. Intranasal delivery of rasagiline (0.24 and 0.6 mg/kg) in powder formulation resulted in significantly reduced peripheral MAO-A inhibitor, compared to respective doses of oral administration of Rasagiline.
The present inventors have further uncovered that intranasal delivery of rasagiline exhibited anti-depressant effect, as demonstrated in widely acceptable tests.
These results indicate that intranasal delivery of rasagiline (e.g., as a mesylate salt thereof), can attain high drug concentrations in the brain that could also inhibit brain MAO-A activity and cause only limited potentiation to induce hypertensive crises ("cheese reaction"). In addition, intranasal delivery of rasagiline may exert overall beneficial effects of the drug via its active potent neuroprotective/neurorestorative metabolites (propargylamine and 1-R-aminoindan) without periphery side effects. These results further indicate that intranasal delivery of rasagiline represents a novel therapeutic approach of the treatment of neuropsychiatric conditions such as depression and/or neuropsychiatric symptoms (e.g., depression) associated with Parkinson's disease.
According to an aspect of some embodiments of the present invention, there is provided a method of treatment, which is effected by administering to the brain of subject a therapeutically effective amount of a MAO-B inhibitor such as Rasagiline.
According to some embodiments of the present invention, the method is effected by administering to the brain of a subject a MAO-B inhibitor is an amount that is capable of treating a neuropsychiatric condition or symptom in a subject in need thereof.
According to some embodiments, a method as described herein is effected by administering to the brain of a subject a MAO-B inhibitor in an amount that is capable of treating (or alleviating) both motor and neuropsychiatry (e.g., depression) symptoms associated with Parkinson's disease.
According to some embodiments, the amount of the MAO-B inhibitor is sufficient to inhibit MAO-A in the brain of the subject.
Since, as described hereinabove, irreversible MAO-B inhibitors exhibit MAO-A inhibition at doses higher than the doses at which they exhibit MAO-B inhibition, administering to the brain of a subject a MAO-B inhibitor is an amount that is sufficient to inhibit MAO-A in the brain of the subject results in inhibition of both, MAO-A and MAO-B in the brain.
A method as described herein can be used for treating neuropsychiatric conditions such as depression, e.g., by means of inhibiting MAO-A in the brain.
A method as described herein can particularly be used for treating Parkinson's disease, and, in some embodiments, for treating motor symptoms and neuropsychiatric (e.g., depression) symptoms associated with Parkinson's disease in a subject in need thereof.
According to some embodiments, a "subject in need thereof is a subject suffering from a neuropsychiatric condition or symptom, such as depression.
According to some embodiments, the subject suffers from Parkinson's disease. Such subjects are also referred to herein and in the art as "Parkinsonian" subjects or patients.
According to some embodiments, the subject is a Parkinsonian subject who suffers, in addition to motor symptoms associated with Parkinson's disease, from neuropsychiatric symptoms (e.g., depression) associated with Parkinson's disease.
According to an aspect of some embodiments of the present invention there is provided a method of treating motor and neuropsychiatric symptoms associated with Parkinson's disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of Rasagiline or a pharmaceutically acceptable salt thereof, wherein said administering is effected by intranasal administration.
As used herein throughout, neuropsychiatric conditions are conditions that result from imbalanced brain activity and include, for example, depression, psychosis, impulse control disorders, cognitive impairment, anxiety, dementia and sleep disturbances. Neuropsychiatric symptoms result from a disease or disorder such as Parkinson's disease, and are used herein to define non-motor symptoms such as, for example, depression, drug-induced psychosis and impulse control disorders, cognitive impairment, anxiety, dementia and sleep disturbances, which may result for the disease's etiology and/or treatment.
As used herein, the term "depression" is interchangeable to the term "depressive illness" and encompasses psychiatric (or mental) conditions known as major depressive disorder, major depression, clinical depression, or simply depression. Such conditions are characterized, for example, by episodes of all-encompassing low mood accompanied by low self-esteem and loss of interest or pleasure in normally enjoyable activities. Depression, or depressive illness, is characterized, for example, by the presence of some or all of following symptoms: (i) depressed mood most of the day, nearly every day, as indicated by either subjective report or observation made by others; (ii) markedly diminished interest or pleasure in all, or almost all, activities most of the day, nearly every day; (iii) significant weight loss when not dieting or weight gain, or decrease or increase in appetite nearly every day; (iv) insomnia or hypersomnia nearly every day; (v) psychomotor agitation or retardation nearly every day; (vi) fatigue or loss of energy nearly every day; (vii) feelings of worthlessness or excessive or inappropriate guilt nearly every day; (viii) diminished ability to think or concentrate, or indecisiveness, nearly every day; and (ix) recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt or a specific plan for committing suicide.
In some embodiments, depression can be determined either behaviorally, according to the above-indicated symptoms, or by well-known tests, such as, but not limited to, according to DSM-IV diagnostic criteria. Similarly, treatment or alleviation of depression can be determined behaviorally, according to the above-indicated symptoms, or by well-known tests, such as, but not limited to, according to DSM-IV diagnostic criteria.
Hereinthroughout, the term "depression" or "depressive illness" refers to both depression as a neuropsychiatric condition per se, and depression symptoms associated with Parkinson's disease. As used herein, motor symptoms associated with Parkinson's disease include, for example, bradykinesia, rigidity, tremor at rest and postural instability.
According to an aspect of some embodiments of the present invention, there is provided a method of treating Parkinson's disease in a subject in need thereof, the method comprising administering to the brain of the subject a pharmaceutical composition comprising a MAO-B inhibitor (Rasagiline or a salt thereof).
According to an aspect of some embodiments of the present invention there is provided a method of treating motor symptoms and neuropsychiatric symptoms (e.g., depression) associated with Parkinson's disease in a subject in need thereof, the method comprising administering to the brain of the subject a pharmaceutical composition comprising a MAO-B inhibitor (Rasagiline or a salt thereof).
According to an aspect of some embodiments of the present invention, there is provided a method of treating a neuropsychiatric condition (e.g., depression) in a subject in need thereof, the method comprising administering to the brain of the subject a pharmaceutical composition comprising a MAO-B inhibitor (Rasagiline or a salt thereof).
In some embodiments, the depression is associated with Parkinson's disease and the subject is a Parkinsonian subject, as defined herein.
In any of the methods described herein, the MAO-B inhibitor (e.g., Rasagiline or a salt thereof) is administered in a pharmaceutical composition comprising the same, as described herein.
According to an aspect of some embodiments of the present invention, there is provided a use of a MAO-B inhibitor (Rasagiline or a salt thereof) in the manufacture of a pharmaceutical composition (a medicament) for the treatment of Parkinson's disease in a subject in need thereof, the pharmaceutical composition being formulated for administration into the brain of the subject (e.g., intranasal administration).
According to an aspect of some embodiments of the present invention, there is provided a use of a MAO-B inhibitor (Rasagiline or a salt thereof) in the manufacture of a pharmaceutical composition (a medicament) for the treatment of motor symptoms and neuropsychiatric symptoms, such as depression, associated with Parkinson's disease in a subject in need thereof, the pharmaceutical composition being formulated for administration into the brain of the subject (e.g., intranasal administration). According to an aspect of some embodiments of the present invention, there is provided a use of a MAO-B inhibitor (Rasagiline or a salt thereof) in the manufacture of a pharmaceutical composition (a medicament) for the treatment of a neuropsychiatric condition (e.g., depression) in a subject in need thereof, the pharmaceutical composition being formulated for administration into the brain of the subject (e.g., intranasal administration).
In some embodiments, the neuropsychiatric condition is associated with Parkinson's disease and the subject is a Parkinsonian subject, as defined herein.
According to an aspect of some embodiments of the present invention, there is provided a pharmaceutical composition comprising a MAO-B inhibitor (Rasagiline or a salt thereof), for use in the treatment of Parkinson's disease in a subject in need thereof, the pharmaceutical composition being formulated for administration into the brain of the subject (e.g., intranasal administration).
According to an aspect of some embodiments of the present invention, there is provided a pharmaceutical composition comprising a MAO-B inhibitor (Rasagiline or a salt thereof), for use in the treatment of motor symptoms and neuropsychiatric symptoms (e.g., depression) associated with Parkinson's disease in a subject in need thereof, the pharmaceutical composition being formulated for administration into the brain of the subject (e.g., intranasal administration).
According to an aspect of some embodiments of the present invention, there is provided a pharmaceutical composition comprising a MAO-B inhibitor (Rasagiline or a salt thereof), for use in the treatment of a neuropsychiatric (e.g., depression) and/or neurodegenerative condition (e.g., Parkinson's disease) in a subject in need thereof, the pharmaceutical composition being formulated for administration into the brain of the subject (e.g., intranasal administration).
In some embodiments, the neuropsychiatric and/or neurodegenerative condition is associated with Parkinson's disease and the subject is a Parkinsonian subject, as defined herein.
In some of any of the embodiments of the methods, uses and compositions described herein, the MAO-B inhibitor (Rasagiline or a salt thereof) is used in an amount that is capable of treating or alleviating depression and/or depressive illness symptoms, or any other neuropsychiatric symptom condition as defined herein, and any combination thereof, including neuropsychiatry symptoms associated with Parkinson's disease.
In some of any of the embodiments of the methods, uses and compositions described herein, the MAO-B inhibitor (Rasagiline or a salt thereof) is used in an amount that is sufficient to inhibit MAO-A inhibition in the brain of the subject.
Thus, according to some embodiments of any one of the methods as described herein, the MAO-B inhibitor (Rasagiline or a salt thereof) is administered in a therapeutically effective amount, and the therapeutically effective amount is an amount sufficient to treat or alleviate a neuropsychiatric (e.g., depression and/or depressive illness) symptoms associated with Parkinson's disease.
Thus, according to some embodiments of any one of the methods as described herein, the MAO-B inhibitor (Rasagiline or a salt thereof) is administered in a therapeutically effective amount, and the therapeutically effective amount is an amount sufficient to inhibit MAO-A in the brain of the subject.
According to some embodiments of any of the compositions and uses as described herein, the composition is used such that an amount of the MAO-B inhibitor (Rasagiline or a salt thereof) administered to the brain of the subject is a therapeutically effective amount as described herein.
According to some embodiments of any of the compositions and uses as described herein, the composition is used such that an amount of the MAO-B inhibitor (Rasagiline or a salt thereof) is sufficient to inhibit MAO-A in the brain of the subject.
According to some embodiments of any of the compositions and uses as described herein, the composition comprises a therapeutically effective amount of the MAO-B inhibitor (Rasagiline or a salt thereof), as described herein.
According to some embodiments of any of the compositions and uses as described herein, the composition comprises an amount of the MAO-B inhibitor (Rasagiline or a salt thereof) which is sufficient to inhibit MAO-A in the brain of the subject.
By "therapeutically effective amount" it is generally meant herein an amount effective to treat, alleviate or ameliorate a disorder or a symptom, or prolong the survival of the subject being treated. In the context of embodiments of the present invention, which relate to an amount effective to treat a neuropsychiatric condition and/or Parkinson's disease and/or motor and neuropsychiatry symptoms associated with Parkinson's disease, the phrase "therapeutically effective amount" describes an amount of a MAO-B inhibitor (Rasagiline or a salt thereof) which is sufficient to alleviate the neuropsychiatric symptom or condition.
By "amount sufficient to inhibit MAO-A in the brain of the subject" it is meant that a pharmaceutical composition comprising a MAO-B inhibitor (Rasagiline or a salt thereof) as described herein comprises an amount of the MAO-B inhibitor (Rasagiline or a salt thereof) which, when administered, inhibits MAO-A in the brain.
In some embodiments, the amount is sufficient to inhibit at least 50 % of the activity of MAO-A in the brain and is some embodiments, the amount is sufficient to inhibit at least 60 5, at least 70 %, at least 80 % or at least 85 % of the activity of MAO- A in the brain of the subject, including higher inhibition values.
The pharmaceutical composition is used at doses and regimens which provide a therapeutically effective amount of the MAO-B inhibitor (Rasagiline or a salt thereof) in the brain of the subject, and in some embodiments, such a therapeutically effective amount causes inhibition of MAO-A in the brain, as is described herein.
In some embodiments of any of the embodiments described herein for any one of the methods, compositions and uses described herein, the therapeutically effective amount of the MAO-B inhibitor (Rasagiline or a salt thereof) is such that inhibits MAO- A in the brain, and administering the composition does not cause "cheese reaction", as described herein. In some embodiments, administering the composition does not result in inhibition of systemic MAO-A (MAO-A in the periphery) or results in reduced inhibition of systemic MAO-A.
In some embodiments of any of the embodiments described herein for any one of the methods, compositions and uses described herein, the composition is used such that inhibition of MAO-A in the brain is effected, yet, "cheese reaction" is not caused. In some embodiments, administering the composition does not result in inhibition of systemic MAO-A (MAO-A in the periphery) or results in reduced inhibition of systemic MAO-A.
The administration of MAO-B inhibitor (Rasagiline or a salt thereof) into the brain, thus bypassing the liver and small intestine, preferably by intranasal administration, allows using wide range of dosing, wherein high doses of the drug will inhibit MAO-A (and MAO-B) in the brain without potentiation of sympathetic cardiovascular activity, i.e., without the side effect resulting from MAO-A inhibition and produced by said MAO-B inhibitor (Rasagiline or a salt thereof) when administered at high doses to the periphery and ingested together with a high tyramine content food (e.g., "cheese reaction").
According to some embodiments of the present invention, the amount of Rasagiline or a salt thereof is such that a ratio of the inhibition of an activity of brain MAO-A to inhibition of an activity of peripheral MAO-A is higher than 1.
In some of these embodiments, such a ratio can be 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, or 2, and even higher.
Such a ratio means, for example, that when the Rasagiline or any other MAO- inhibitor is administered to the subject and exhibits, for example, inhibition of 50 % of the MAO-A activity in the brain, the inhibition of peripheral MAO-A is lower than 50 %, and can be, for example, 40 %, 30 %, 20 % and even lower. Similarly, for inhibition of 80 % of MAO-A activity in the brain, inhibition of peripheral MAO-A is lower than 80 %, or lower than 70 %, or lower than 40 %, or lower than 30 %.
In some of these embodiments, the above-described ratio is higher than the same ratio when Rasagiline or a salt thereof is administered orally or intraperitoneally. In some embodiments, the ratio is higher by 10 5, 20%, 30 %, 40 %, 50 % and even more compared to the same ratio when oral or IP administration is effected.
According to some of any of the embodiments described herein, the pharmaceutical composition and/or the mode of administration (e.g., intranasal administration) are configured such that the above-indicated amount of the MAO-B inhibitor (e.g., Rasagiline or a salt thereof) is present in a brain of a subject following the administration.
In some embodiments, the composition and/or a mode of the intranasal administration are configured such that following the administration, an amount of rasagiline in the brain of the subject is such that inhibits at least 50 % or at least 80 % of an activity of MAO-A in the brain.
In some embodiments, the composition and/or a mode of the intranasal administration are configured such that following the administration, an amount of Rasagiline in the brain of the subject is such that a ratio of the inhibition of an activity of brain MAO-A to inhibition of an activity of peripheral MAO- A is higher than 1, as described herein.
In some of any of the embodiments described herein, the method and pharmaceutical composition as described herein result in inhibition of both MAO-B and MAO-A in the brain.
In some of any of the embodiments described herein, the concentration of the pharmaceutically active agent, i.e., the MAO-B inhibitor as defined herein (Rasagiline or a salt thereof), in a pharmaceutical composition is determined in accordance with the particular agent chosen; its efficacy; a comparison of its bioavailability by the particular mode of administration used, e.g., intranasal administration, and by other routes of administration, e.g., parenteral injection or oral administration; and the desired frequency of administration combined with the desired single dosage of the formulation. Such pharmacological data can routinely be obtained by the skilled artisan from animal experiments, e.g., in terms of index values. Exemplary animal experiments are provided in the Examples section that follows.
The dosage administered, for example, to a particular Parkinsonian patient will depend on the state of that patient, and will be determined as deemed appropriate by the practitioner.
Thus, according to some of any of the embodiments of the present invention, the pharmaceutical composition is formulated and used (administered to the brain at a certain regimen) so as to deliver to the brain a MAO-B inhibitor (Rasagiline or a salt thereof) as described herein in an amount as described herein. As discussed herein, such an amount inhibits MAO-A in the brain and may optionally also inhibit MAO-B in the brain.
In some of these embodiments, the pharmaceutical composition is formulated and used (administered to the brain at a certain regimen) so as to deliver to the brain a MAO-B inhibitor as described herein in an amount that does not substantially inhibit systemic MAO-A, namely, MAO-A present in the periphery, for example, in liver and small intestine.
In some embodiments, any one of the compositions, uses and methods as described herein, the MAO-B inhibitor used (or a composition comprising the MAO-B inhibitor) is administered intranasally and hence directly into the brain. Without being bound by any particular theory, administration of MAO-B inhibitor or the brain bypasses the circulation and in particular the liver and small intestine thus avoiding the undesired side effect produced by inhibition of the MAO-A enzyme in these tissues.
Intranasal administration is a noninvasive means for targeting the brain by passing the BBB, minimizing systemic absorption, and limiting potential peripheral side effects. Intranasal administration allows the drug administered to travel through the roof of the nose, along the fibers of the olfactory and trigeminal nerves found in the mucosa of the nose, directly to the extracellular space of the neurons of the brain and spinal cord without having to cross the BBB or access the blood stream, and consequently, without exposing the other organs of the body to the drug, thus reducing its side effects and required dosage.
In some embodiments of the present invention, other modes of administrations are contemplated. These include, for example, local administration to the brain, for example, by intrastriatal administration, i.e., directly to the corpus striatum of the individual treated, ocular administration, and the like. Such modes of administration typically utilize liquid compositions. Thus, in any of the compositions and methods described herein, intranasal administration can be replaced by local, ocular or other modes for directly administering the MAO-B inhibitor to the brain.
Administration of the composition as described herein can be effected once daily, or twice daily, or once every two days. In some embodiments, administration is effected so as to maintain an amount of the MAO-B inhibitor (e.g., Rasagiline) in the brain of the subject, which inhibits MAO-A in the brain, as described herein.
As used herein, a "pharmaceutical composition" refers to a preparation of an active compound (e.g., a MAO-B inhibitor such as Rasagiline or a salt thereof), with other chemical components such as pharmaceutically acceptable and suitable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism, i.e., to the brain of the subject, as described herein.
Hereinafter, the term "pharmaceutically acceptable carrier" refers to a carrier or a diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound. Examples, without limitations, of carriers are: propylene glycol, saline, emulsions and mixtures of organic solvents with water, as well as solid (e.g., powdered) and gaseous carriers.
Herein the term "excipient" refers to an inert substance added to a pharmaceutical composition to further facilitate administration of a compound. Examples, without limitation, of excipients include calcium carbonate, calcium phosphate, various sugars (e.g., dextrose) and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.
In some embodiments, the pharmaceutical composition is identified or indicated for administration once per day (e.g., as described herein).
In some embodiments, the pharmaceutical composition comprises a unit dosage form, comprising a therapeutically effective amount of a MAO-B inhibitor, as described herein.
The term "unit dosage form", as used herein, describes physically discrete units, each unit containing a predetermined quantity of MAO-B inhibitor calculated to produce the desired therapeutic effect, in association with at least one pharmaceutically acceptable carrier, diluent, excipient, or combination thereof.
In some embodiments, the amount of MAO-B inhibitor in the unit dosage form may optionally be a daily dosage of the MAO-B inhibitor, as described herein, such that a method or treatment such as described herein may be effected by administration of one unit dosage form per day.
Alternatively, the amount of the MAO-B inhibitor in the unit dosage form may be, for example, half a daily dosage described herein, such that a method or treatment described herein may be effected by administration of two unit dosage forms per day; or a third or a quarter of a daily dosage described herein, such that a method or treatment described herein may be effected by administration of three or four unit dosage forms per day, respectively.
Further alternatively, the pharmaceutical composition is formulated such that a single dosage of the composition contains a desired amount of the MAO-B inhibitor, as described herein, or can be formulated into a device or a delivery system that dispenses or releases a desired amount of the MAO-B inhibitor as described herein into the brain of a subject. The pharmaceutical composition comprising the MAO-B inhibitor according to any one of the embodiments relating to the methods, uses and compositions, as described herein, can be prepared by conventional techniques, e.g., as described in Remington: The Science and Practice of Pharmacy, 19th Ed., 1995.
Pharmaceutical compositions of the present invention may be manufactured by processes well known in the art, e.g., by means of conventional mixing, dissolving, granulating, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.
Pharmaceutical compositions for use in accordance with the present invention thus may be formulated in conventional manner using one or more pharmaceutically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the MAO-B inhibitor (Rasagiline or a salt thereof) into preparations which can be used pharmaceutically and administered to the brain of a subject. Proper formulation is dependent upon the route of administration chosen.
The compositions can be prepared, e.g., by uniformly and intimately bringing the active agent, i.e., a MAO-B inhibitor (Rasagiline or a salt thereof), as defined above, into association with a pharmaceutically acceptable carrier, such as a liquid carrier, a
(e.g., finely divided) solid carrier, or both, and then, if necessary, shaping the product into the desired formulation.
Preferably, the carrier is selected so as to reduce nasal absorption of the rasagiline, to thereby increase the amount of the drug that reaches the brain.
Depending on the carrier selected, the composition may be in liquid, solid or semisolid form and may further include pharmaceutically acceptable fillers, carriers, diluents or adjuvants, and other inert ingredients and excipients.
In some of any one of the embodiments described herein, the pharmaceutical composition of the present invention is formulated in a solid form, e.g., as a powder and/or as nanoparticles.
In some of any one of the embodiments described herein, the powder formulation comprises, or consists of, a sugar, as described herein (e.g., dextrose, lactose, sucrose, mannitol, or sorbitol), as an acceptable carrier. The pharmaceutical composition can be formulated for any suitable route of administration that may deliver the active agent directly into the brain, as described herein, and is preferably formulated for intranasal administration.
A pharmaceutical composition formulated for intranasal administration may be liquid, e.g., adapted for administration as a spray or drops. Liquid preparations, such as those based on aqueous formulations, may include ancillary agents, e.g., a pH-buffering system, for example, a buffer such as phosphate, borate, citrate or acetate buffers, a preservative, and an osmotic pressure controlling agent, e.g., glycerol or sodium chloride.
Non limiting examples of buffering agents/systems include boric acid, sodium bicarbonate, sodium citrate, sodium acetate, sodium phosphate monobasic, sodium phosphate dibasic, sodium phosphate dibasic heptahydrate, potassium dihydrogen phosphate, and combinations thereof such as combinations of boric acid and sodium bicarbonate, sodium phosphate monobasic and sodium phosphate dibasic, or sodium citrate and citric acid. If a buffering agent is employed, it is chosen in quantities that preferably do not irritate the nasal mucosa.
In some of these embodiments, the carrier is an aqueous carrier, e.g., water. Such preparations may be prepared by dispersing the active agent, i.e., the MAO-B inhibitor as defined herein (Rasagiline or a salt thereof), and ancillary agents, utilizing any method usually employed for suspension or emulsification, e.g., ultrasonic treatment. Adjustment of the aqueous phase to neutrality, i.e., to pH in the range from about 6.5 to about 8, may be accomplished in any of the preparatory steps.
In some embodiments, microemulsions for intranasal administration are prepared in which the size of the dispersed particles or droplets is of the order of 10 nm, thereby facilitating their passage across the nasal mucosa. Such microemulsions may be sterilized by filtration.
In certain embodiments, the pharmaceutical composition includes one or more agents that increase viscosity, chosen in quantities that preferably do not irritate the nasal mucosa and increase nasal retention time. Examples of agents that increase viscosity include, without being limited to, methylcellulose, carboxymethylcellulose sodium, ethylcellulose, carrageenan, carbopol, and combinations thereof. The pharmaceutical composition may contain aqueous diluents, e.g., saline, water, dextrose, and combinations thereof, and/or non-aqueous, e.g., alcohols, particularly polyhydroxy alcohols such as propylene glycol, polyethylene glycol, and glycerol, vegetable oils and mineral oils. These aqueous and non-aqueous diluents can be added in various concentrations and combinations to form solutions, suspensions, oil-in-water emulsions or water-in-oil emulsions.
The pH of the compositions may be adjusted to the desired value using any suitable organic or inorganic acid or organic or inorganic base. Suitable organic acids include, without limiting, acetic acid, citric acid, glutamic acid and methane sulfonic acid. Suitable inorganic acids include, but are not limited to, hydrochloric acid and sulphuric acid. Suitable organic bases include, without limiting, meglumine, lysine and tromethamine. Suitable inorganic bases include, without being limited to, sodium hydroxide and potassium hydroxide.
Solvents that may be used to prepare the pharmaceutical compositions of the invention include, without being limited to, water, ethanol, propylene glycol, polyethylene glycol, glycerin, phenol, glycofurol, benzyl benzoate and polyoxyethylene castor oil derivatives.
In a preferred embodiment of any of the aspects described herein, the pharmaceutical composition is in a solid form, and comprises pharmaceutically acceptable solid carrier.
Suitable carriers and/or excipients include, for example, fillers such as sugars, including dextrose, lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose; and/or physiologically acceptable polymers such as polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
In some of any of the embodiments described herein, the carrier includes sacchraride (sugar) as a filler, for example, dextrose, lactose, sucrose, mannitol, or sorbitol. For administration by inhalation (e.g., intranasal administration), the MAO-B inhibitor can be conveniently delivered in the form of an aerosol spray presentation (which typically includes powdered, liquefied and/or gaseous carrier) from a pressurized pack or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane or carbon dioxide. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, e.g., gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of MAO-B inhibitor (Rasagiline or a salt thereof) and a suitable powder base such as, but not limited to, lactose or starch.
Pharmaceutically acceptable excipients such as dispersing agents, isotonicity agents, stabilizing agents, and the like can be used as appropriate in the pharmaceutical compositions. The pharmaceutical compositions of the invention may contain excipients such as antioxidants, chemical preservatives, buffering agents, agents that increase viscosity, diluents, pH adjusters, and solvents.
Antioxidants are substances that prevent oxidation of the formulations. Suitable antioxidants for use in the compositions of the invention include, without being limited to, butylated hydroxytoluene, butylated hydroxyanisole, potassium metabisulfite, and the like.
In certain embodiments, the pharmaceutical composition of the present embodiments contains a preservative chosen in quantities that preserve the composition but do not cause irritation of the nasal mucosa. Examples of suitable preservatives include, without limiting, benzalkonium chloride, methyl, ethyl, propyl- or butylparaben, benzyl alcohol, phenylethyl alcohol, benzethonium, and combinations thereof.
The pharmaceutical compositions of the present embodiments may contain other pharmaceutically acceptable ingredients well known in the art. Such excipients include, without limiting, chelating agents such as edetic acid or a salt thereof, flavors, sweeteners, thickening, adhesive or gelling agents, e.g., celluloses such as methylcellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, sodium carboxyl cellulose and microcrystalline cellulose, poloxomers, polyethylene glycols, carbomers or polyethylene oxide. The pharmaceutical compositions of the present invention, when formulated for intranasal administration, may be used in any dosage dispensing device adapted for intranasal administration. The device should be constructed with a view to ascertaining optimum metering accuracy and compatibility of its constructive elements.
The pharmaceutical composition and the device for dispensing it can be administered to a single nostril or to both nostrils. In some embodiments, it is administered to both nostrils.
According to an aspect of some embodiments of the present invention, there is provided a device, or a delivery system, configured for intranasal administration of a pharmaceutical composition comprising a MAO-B inhibitor (Rasagiline or a salt thereof) as described herein to a subject.
In some embodiments, the device is configured for dispensing the composition, from a container comprising the composition, and may comprise means for dispensing a pre-determined dose of the composition from the container and delivering said dose intranasally.
In some embodiments, the pre-determined dose is such that when administered intranasally, results in an amount of the MAO-B inhibitor in the brain which is a therapeutically effective amount, as described herein, and/or is sufficient to inhibit MAO-A in the brain, as described herein. In some embodiments, a system for intranasal administration of Rasagiline or a pharmaceutically acceptable salt thereof as described herein, comprises means for dispensing a pre-determined dose of Rasagiline or a salt thereof and for intranasally delivering the pre-determined dose, which is effective for alleviating neuropsychiatric and motor symptoms associated with Parkinson's disease, as described herein.
In some embodiments, a system for intranasal administration of Rasagiline or a pharmaceutically acceptable salt thereof as described herein, comprises means for dispensing a pre-determined dose of Rasagiline or said salt thereof and for intranasally delivering the pre-determined dose, which is g effective for treating neuropsychiatric and/or neurodegenerative conditions in a subject in need thereof, as described herein.
The compositions may be administered as drops, sprays, aerosols or by any other intranasal dosage form or a dosage form for administering into the brain, as described herein. Optionally, the delivery system may be a unit dose delivery system. The volume of solution, powder or suspension delivered per dose may be anywhere from 10 to 10000 μΐ and preferably 1000-5000 μΐ.
Delivery systems for these various dosage forms may be dropper bottles, plastic squeeze units, atomizers, nebulizers, metered nasal sprayers, metered-occular sprays, or pharmaceutical aerosols in either unit dose or multiple dose packages.
Aerosol systems require a propellant to be inert towards the formulation. Suitable propellants may be selected among such gases as fluorocarbons, hydrocarbons, nitrogen and dinitrogen oxide or mixtures thereof.
In some embodiments, the device is configured for dispensing a composition, as described herein, wherein the composition is a solid compotation (e.g., in a powder form).
According to any one of the embodiments described herein, the MAO-B inhibitor is Rasagiline (N-propargyl-l-(R)-aminoindan) or a salt thereof.
In particular embodiments, in any of the methods, compositions, uses and devices described herein, the MAO-B inhibitor is Rasagiline or a pharmaceutically acceptable salt thereof.
Non-limiting examples of pharmaceutically acceptable salts of Rasagiline include the mesylate salt; the esylate salt; the maleate salt; the fumarate salt; the tartrate salt; the sulfate salt; the hydrochloride salt; the hydro bromide salt; the p- toluenesulfonate salt; the benzoate salt; the acetate salt; or the phosphate salt of rasagiline.
Pharmaceutically acceptable salts of rasagiline may be prepared according to any suitable technique known in the art, e.g., as described in detail in US 5,532,415.
In preferred embodiments, the Rasagiline is used as a mesylate salt of Rasagiline.
In any one of the embodiments described herein, the MAO-B inhibitor (e.g., Rasagiline) can be in any of the possible stereoisomers or enantiomers, or as a mixture of two or more stereoisomer sot enantiomers, or as a racemic mixture.
In some of any the embodiments described herein, an amount of Rasagiline or a salt thereof administered to the brain of the subject is lower than an amount equivalent to 10 mk/kg per day in rats, that is, lower than the amount required for inhibiting MAO- A in the brain when Rasagiline or a salt thereof is administered orally or IP. In some of any the embodiments described herein, an amount of Rasagiline or a salt thereof administered to the brain of the subject is higher than an amount equivalent to 1 mg per day in humans.
An amount of 1 mg in humans is equivalent to about 0.1 mg/kg in rats.
In some embodiments, the amount is higher than 2 mg, and in come embodiments, the amount is 1.1, 1.5,1.8, 2, 2.5, 3, 3.5, 4, 4.5, 5 or higher, including any intermediate value or subranges between said values.
In some embodiments, an amount of Rasagiline or a salt thereof administered to the brain of the subject is higher than an amount equivalent to 0.1 mg/kg in rats, and can range, for example, from an amount equivalent to 0.2 mg/kg in rats to 6 mg/kg in rats, including any value and subrange therebetween.
Other MAO-B inhibitors, such as selegiline (( ?)-N-methyl-N-(l-phenylpropan- 2-yl)prop-l-yn-3-amine; L-depreny; Eldepryl), and optionally safinamide (7V2-{4-[(3- fluorobenzyl)oxy]benzyl}-L-alaninamide), or a pharmaceutically acceptable salt thereof, can be used instead of Rasagiline.
As shown in the Examples section that follows, the present inventors have shown that a methodology can be used for improving the ratio of inhibiting an activity of MAO-A such that inhibition of brain MAO-A is higher than inhibition of peripheral (e.g., liver and/or intestine) MAO-A, namely that the ratio between inhibition of brain and peripheral MAO-A is higher than 1. Such an improvement, when compared, for example, to the ratio obtained when Rasagiline or a salt thereof is administered orally or IP, is advantageous, for example, as it reduced the side effects associated with inhibiting peripheral MAO-A, yet allows to obtain higher amount of the drug in the brain and thus benefit from additional therapeutic effect such as alleviation or treatment of neuropsychiatric symptoms and/or conditions, as described herein.
Such a methodology can be used by mode of administrations other than intranasal administration, or any other administration to the brain, as described herein.
According to an aspect of some embodiments of the present invention there is provided a method of treating a neuropsychiatric and/or neurodegenerative condition is a subject in need thereof, which comprises administering to the subject a therapeutically effective amount of Rasagiline or a pharmaceutically acceptable salt thereof, wherein administration is effected at a dose and/or a mode of administration selected such that a ratio of the inhibition of an activity of brain MAO -A to inhibition of an activity of peripheral MAO-A in the subject is higher than 1, as described in any one of the respective embodiments herein.
According to an aspect of some embodiments of the present invention there is provided a system configured for administering Rasagiline or a pharmaceutically acceptable salt thereof to a subject in need thereof, the system comprising means for delivering Rasagiline or a salt thereof to the subject, wherein the means are such that upon delivering Rasagiline or said salt thereof, a ratio of the inhibition of an activity of brain MAO-A to inhibition of an activity of peripheral MAO-A in the subject is higher than 1, according to any one of the respective embodiments described herein.
Exemplary modes of administration and corresponding systems include, without limitation, transdermal administration, e.g., via a patch; topical administration; local administration to the brain by, e.g., injection or by guided therapy; and intranasal administration and corresponding systems as described herein.
Further according to some embodiments of the present invention, any of the methods and systems and compositions as described herein can be utilized for improving the efficacy of Rasagiline or a salt thereof by means of activities exerted by its metabolites, particularly by the l-(R)-amino indan.
As shown in the Examples section that follows, and has been previously described, this metabolite may exhibit additional therapeutic effects such as neuroprotective and neurorestorative effects in the brain. Using the compositions, methods and systems as described herein should result in enhanced concentration of this metabolite in the brain and thus by additional therapeutic effects of a composition comprising Rasagiline or a salt thereof, as described herein.
The methods, compositions and systems as described herein, which account for a relatively high amount of Rasagiline in the brain, and hence, presumably for a relatively high amount of its metabolites in the brain, can be beneficially used for treating various neurodegenerative and neuropsychiatric conditions that can be treated by the aminoindan metabolite, and, for example, by its neuroprotective and neurorestorative effect. These conditions include any one of the conditions listed in the Examples section hereinbelow and those which have been previously described, including Parkinson's disease per se and a neuropsychiatric condition. In any one of the compositions, methods, uses and devices as described herein, the MAO-B inhibitor can be used in combination with an additional active agent or drug, for example, an anti-Parkinsonian drug such as 1-DOPA.
It is expected that during the life of a patent maturing from this application many relevant MAO-B inhibitors will be developed and the scope of the term MAO-B is intended to include all such new technologies a priori.
As used herein the term "about" refers to ± 10 %.
The terms "comprises", "comprising", "includes", "including", "having" and their conjugates mean "including but not limited to".
The term "consisting of means "including and limited to".
The term "consisting essentially of" means that the composition, method or structure may include additional ingredients, steps and/or parts, but only if the additional ingredients, steps and/or parts do not materially alter the basic and novel characteristics of the claimed composition, method or structure.
As used herein, the singular form "a", "an" and "the" include plural references unless the context clearly dictates otherwise. For example, the term "a compound" or "at least one compound" may include a plurality of compounds, including mixtures thereof.
Throughout this application, various embodiments of this invention may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.
Whenever a numerical range is indicated herein, it is meant to include any cited numeral (fractional or integral) within the indicated range. The phrases "ranging/ranges between" a first indicate number and a second indicate number and "ranging/ranges from" a first indicate number "to" a second indicate number are used herein interchangeably and are meant to include the first and second indicated numbers and all the fractional and integral numerals therebetween.
As used herein the term "method" refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the chemical, pharmacological, biological, biochemical and medical arts.
As used herein, the term "treating" includes abrogating, substantially inhibiting, slowing or reversing the progression of a condition, substantially ameliorating clinical or aesthetical symptoms of a condition or substantially preventing the appearance of clinical or aesthetical symptoms of a condition.
It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination or as suitable in any other described embodiment of the invention. Certain features described in the context of various embodiments are not to be considered essential features of those embodiments, unless the embodiment is inoperative without those elements.
Various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below find experimental support in the following examples.
EXAMPLES
Reference is now made to the following examples, which together with the above descriptions illustrate some embodiments of the invention in a non limiting fashion.
EXAMPLE 1
Materials and Methods:
Rasagiline (mesylate salt), was used.
Adult (3 -month old) male Sprague Dawley rats, weighing about 250 grams, were from Harlan Laboratories, Inc Israel. Rasagiline (0.1 and 0.3 mg/kg) and vehicle were administered intraperitonealy (IP) and intranasally (NAS) to adult male Sprague Dawley rats (n=4 per each experimental group). The animals were sacrificed 1 hour after the treatment; the brains and livers were rapidly removed and dissected; and the effect of rasagiline, given at the two different regimens (IP and NAS) on MAO- A and MAO-B activities was examined in the brain and liver, as previously described (Tipton et al., 1982).
Results:
The inhibition of MAO-A and MAO-B in the brain by IP and NAS administration of Rasagiline is presented in Figures 1 and 2, respectively.
Figure 1 demonstrates that rasagiline (0.3 mg/kg) significantly inhibited brain MAO-A inhibition by using NAS delivery compared to IP administration. Figure 2 demonstrates that no significant difference in brain MAO-B inhibition is observed between the two modes of drug administration.
The inhibition of MAO-A and MAO-B in the liver by IP and NAS administration of Rasagiline is presented in Figures 3 and 4, respectively.
Figure 3 demonstrates that rasagiline (0.3 mg/kg) significantly inhibited liver MAO-A inhibition when administered IP, compared to NAS delivery. No significant differences in liver MAO-B inhibition were observed between the two modes of drug administration, as shown in Figure 4.
EXAMPLE 2
Intranasal administration of powder and liquid formulations of Rasagiline (as a mesylate salt) was tested for inhibition MAO-A in the brain and periphery.
Materials and Methods:
All procedures were carried out in accordance with the National Institutes of Health Guide for care and Use of Laboratory Animals, and were approved by the Animal Ethics Committee of the Technion, Haifa, Israel.
A mesylate salt of Rasagiline was used in all experiments. Powder formulation of rasagiline was prepared using a dextrose filler. Liquid formulation of rasagiline was prepared in water as a vehicle. Control liquid formulations included vehicle only.
Adult (3 months-old; about 250 grams weight) male Sprague Dawley rats (obtained from Harlan Laboratories, Inc Israel) were administered intranasally with a 5 ml puff of a powder formulation of rasagiline in dextrose (0.24, 0.6, 1.5 and 6 mg/kg) or liquid formulation of Rasagiline in water vehicle (0.6 and 6 mg/kg), or respective vehicle (controls). The animals were acutely administered intranasally and sacrificed 4 hours following drug/vehicle administration. The brain regions, hippocampus and striatum, as well as the small intestine were dissected out. All tissues were frozen at - 80° C for further analysis.
The effect of different doses of intranasal treatment of rasagiline (in powder formulation and in liquid formulation) on MAO-A and MAO-B activity, was measured in the striatum, hippocampus and small intestine, according to Tipton et. al. (1982). In brief, samples were dissected out at 4 °C and homogenized. Homogenates were incubated with [C14] serotonin for 30 minutes (final concentration 100 μΜ) as a substrate for MAO-A, or with [C14]phenylethylamine for 20 minutes (final concentration 100 μΜ) as a substrate for MAO-B. The radioactivity was determined by liquid- scintillation .
Results:
The effect of acute intranasal delivery of rasagiline, given in powder or liquid formulation, on rat striatal and hippocampal MAO-A and MAO-B and on striatum/small intestine MAO-A ratio, was measured.
The obtained data is presented in Figures 5-7 and in Tables 1-3.
As shown in Figure 5 and Table 1, intranasal (I.N.) delivery of rasagiline in powder formulation at 0.6 mg/kg caused a significant higher inhibition of striatal MAO- A activity, compared to the same dose of rasagiline delivered in liquid formulation in rats.
Table 1 (MAO-A inhibition)
Figure imgf000039_0001
As further shown in Table 1, and in Figure 6, intranasal (I.N.) treatments of giline (0.24, 0.6, 1.5 and 6 mg/kg) in powder formulation dose-dependently inhibited MAO-A activity in rat striatum and hippocampus, while more than 90 % MAO-A inhibition was observed at a dose of 6 mg/kg (in powder formulation).
Table 2 below presents the data obtained for MAO-B inhibition. As shown therein, Rasagiline (at doses ranging from 0.24 to 6 mg/kg) at both powder and liquid formulations, significantly inhibited (about 98 %; p<0.05) MAO-B activity in the striatum and hippocampus of drug-treated rats, compared to respective vehicle-treated animals (not shown).
Table 2 (MAO-B Inhibition)
Figure imgf000040_0001
Table 3 below and Figure 7 present the ratio of MAO-A inhibition in the CNS vs. the periphery, represented by the ratio of MAO-A inhibition in striatum/ Hippocampus and intestines or striatum/Hippocampus and liver, upon intranasal (I.N.) delivery of rasagiline, at variables doses in powder formulation. As shown therein, a dose of 0.6 mg/kg intranasally delivered Rasagiline resulted in the highest ratio of % MAO-A inhibition in the striatum vs. small intestine.
Table 3 (Ratio of CNS/Peripheral MAO-A inhibition)
Figure imgf000040_0002
EXAMPLE 3
Studies were conducted for determining the potency of intranasal vs. oral administration of Rasagiline in inhibition of MAO-A in the striatum. Materials and Methods:
All procedures were carried out in accordance with the National Institutes of Health Guide for care and Use of Laboratory Animals, and were approved by the Animal Ethics Committee of the Technion, Haifa, Israel.
A mesylate salt of Rasagiline was used.
Powder formulation of rasagiline was prepared in dextrose.
Liquid oral formulation of rasagiline was prepared in water as a vehicle.
Control liquid formulations included vehicle only.
Adult (3 months-old; about 250 grams weight) male Sprague Dawley rats (obtained from Harlan Laboratories, Inc Israel), weighing approx. 250 grams were administered intranasally (IN) a 5 ml puff of Rasagiline (mesylate salt), prepared in dextrose as powder formulation, per-os (P.O) Rasagiline prepared in water) (0.24 and 0.6 mg/kg) or respective vehicle (controls). The animals were acutely administered and sacrificed 4 hours following drug/vehicle administration. The brain regions, hippocampus and striatum, as well as the small intestine were dissected out. All tissues were frozen at -80 °C for further analysis.
The effect of different doses of intranasal or oral treatment of rasagiline (0.24 and 0.6 mg/Kg) on MAO-A and MAO-B activity in acute-treated rats, was measured according to Tipton et. al. (1982, supra).
Results:
Figures 8 A and 8B present the effects of acute intranasal delivery vs. oral administration of rasagiline on rat striatal and hippocampal MAO-A and MAO-B, respectively, and the ratio of striatal/small intestinal MAO-A inhibition, respectively.
As shown therein, Rasagiline at both tested concentrations (0.24 and 0.6 mg/Kg) significantly increased MAO-A inhibition activity in rat striatum and hippocampus following intranasal drug delivery (powder formulation), compared to oral administration. Rasagiline at both regimens significantly inhibited (about 99 %; p<0.05) MAO-B activity in the striatum and hippocampus of drug-treated rats (data not shown).
Figure 9 presents the ratio of % MAO-A inhibition in the striatum/small intestine, and shows that Rasagiline exerted significantly lower MAO-A inhibition in the periphery (small intestine) following intranasal delivery, compared to P.O. administration. EXAMPLE 4
The tail suspension test (TST) is one of the most widely used models for assessing antidepressant- like activity in mice, based on the fact that animals that are subjected to short-term, inescapable stress by being suspended by their tail, will develop an immobile posture [Cryan, et al. Neurosci Biobehav Rev, 2005. 29: 571-625]. The TST was assayed using Rasagiline (0.2 mg/kg) and its metabolite l-(R)-aminoindan (5 mg/kg), vs. control, and the results are presented in Figure 10. It is shown that the duration of immobility of vehicle-treated aged rats was higher than vehicle-treated young animals. It is further shown that both rasagiline and l-(R)-aminoindan reduced the duration of immobility of drug-treated aged rats, compared to vehicle-aged group.
EXAMPLE 5
Additional in vivo studies have shown an effect of l-(R)-aminoindan on various neuroprotective and neurorescue parameters such as behaviour and cognition, memory acquisition, hippocampal function, levels of striatal catecholamines, antioxidant effect in the frontal cortex, and more. The following describes some of the results obtained in these studies.
Materials and Methods:
Rats (Male Sprague-Dawley rats, purchased from Harlan, Jerusalem, Israel) were randomly divided into four groups (7-9 animals in each experimental group): groups 1-3 were administrated rasagiline intranasally (IN) at doses of 0.02, 0.2 and 2 mg/kg, respectively; groups 4-5 were administrated with rasagiline orally (PO) at doses of 0.2 and 2 mg/kg, respectively; groups 6-7 were administrated either saline for the IN regimen or highly purified water in oral regimen.
IN rasagiline was administered in a powder formulation containing dextrose. PO rasagiline was administered in a formulation containing water.
All rats were treated 3 times a week, for 4 weeks. For the IN administration, rats were deeply anesthetized using a (2: 1) Ketamine/ xylazine solution, and the rats in the oral treated groups were undergoing the same procedure. The concentrations of rasagiline were determined based on previous chronic oral treatment in rats [Youdim, et al., 2001, Br J Pharmacol.132(2):500-6]. The animals were sacrificed by decapitation, and striatum, hippocampus, cerebellum, liver and small intestine have been removed rapidly and frozen in liquid nitrogen for further analyses.
Effect of IN and PO administration of rasagiline on antidepressant-like behavior in rats:
The possible antidepressant-like effects of rasagiline administered IN or orally to rats, was examined by using open field test (OFT) [Durand et al. 2000. Neuropharmacology 39(12), 2464-77; Santiago et al. 2014. Behav Brain Res 259, 70-7], and forced swimming test (FST) [Porsolt, et al., 1978, Eur J Pharmacol 47(4), 379-91; Gordon, et al., 1999, Pharmacol Biochem Behav 63(3), 501-6].
Figure 11A shows the effects of IN and oral rasagiline administration on exploration and anxiety behavior of rats, using the OFT. Treatment with IN delivery of rasagiline (0.02-2 mg/kg) dose-dependently increased the time spending in the center in the tested area (up to 9.5 + 1.3 % of the controls, at 2 mg/kg), while treatment with PO administration of rasagiline had no effect (up to 2 mg/kg). As shown in Figure 11B, there was no difference in the total distance between all treated groups.
The data obtained in the FST is presented in Figure 12. As shown therein, IN administration of rasagiline showed a dose-dependent reduction in the immobility time of drug-treated rats (up to 9.8 + 2.9 % of the controls, at 2 mg/kg) compared to vehicle- treated rats. PO administration of rasagiline did not show any significant effect on the duration of immobility in drug-treated rats. These behavioral findings indicate that the IN administration of rasagiline at 0.02-2 mg/kg may exert an antidepressant-like effect, while PO administration of rasagiline at the same doses did not show a significant antidepressant-like effect.
Effect of IN and PO rasagiline administration on MAO-A and MAO-B activity in brain and periphery and cerebral catecholamine levels in rats:
The effect of IN and PO administration of rasagiline on MAO-A and MAO-B activity in several brain regions and periphery and on the levels of amines and their metabolites in the striatum and hippocampus was tested, as previously described, using HPLC analysis with appropriate catecholamine and metabolite standards, as previously described.
The obtained data is presented in Figures 13 and 14. As shown in Figures 13A- 13D, IN administration of rasagiline (0.2 and 2 mg/kg) significantly and dose- dependency inhibits MAO-A activity in the striatum (Figure 13A), hippocampus (Figure 13B), liver (Figure 13C) and intestine (Figure 13D).
As shown in Figures 14A-14D, the MAO-A inhibition ratios of striatum/intestine (Figure 14A), hippocampus/intestine (Figure 14B) and hippocampus/liver (Figure 14D) were significantly higher following IN administration, compared to PO administration of rasagiline (0.2 mg/kg). A dose of 0.2 mg/kg rasagiline, administered either IN or PO, resulted in almost complete inhibition of MAO-B in the striatum and hippocampus (> 85 %), as shown in Figure 14D.
HPLC analyses were performed using a UV detector and appropriate standards. The obtained data is presented in Figures 15-18.
Figures 15A-D show the data obtained in HPLC analysis of striatal dopamine (DA) and its metabolites following the above-indicated treatments. As shown therein, IN and PO treatment with rasagiline (0.2 and 2 mg/kg) led to increased DA levels (Figure 15A), whereas reduced levels of intraneuronal DA metabolites, 3,4- dihydroxyphenylacetic acid (DOPAC) (see, Figure 15B) and homovanillic acid (HVA) (see, Figure 15C) and elevated levels of the extraneuronal metabolite and 3- methoxytyramine (3-MT) (see, Figure 15D), were found. At 0.2 mg/kg of rasagiline, striatal DA levels were slightly higher in the IN treatment, compared to the PO-treated group (see, Figure 15A).
In addition, DOPAC/DA (see, Figure 16 A) and HVA/DA (see, Figure 16B) ratios were significantly decreased following IN, compared to PO, administration of rasagiline (0.2 mg/kg). The ratios 3-MT/DA (Catechol-O-methyltransferase (COMT)- associated methylation pathway) and 3-MT/DOPAC (DA reuptake index) were significantly higher following IN, compared to PO, administration of rasagiline (2 mg/kg) (see, Figures 16C and 16D, respectively).
Figures 17A-D show data obtained for the level of serotonin and its metabolite, and of norepinephrin, following the above-indicated treatments. As shown therein, the IN administration of rasagiline (0.02-2 mg/kg) significantly and dose-dependently increased the levels of striatal serotonin (5-HT) (see, Figure 17A) and reduced the levels of 5-HT metabolite, 5-hydroxyindoleacetic (5-HIAA) (see, Figure 17B). Striatal 5-HT levels were significantly higher in IN-treated rats with rasagiline (2 mg/kg), compared to PO-treated rats. The 5-HIAA/5-HT ratio was significantly decreased following IN, compared to PO, administration of rasagiline (0.2 and 2 mg/kg) (see, Figure 17C). IN administration of rasagiline (2 mg/kg) also resulted in increased norepinephrine (NE) levels, which were higher compared to PO administration (see, Figure 17D).
As shown in Figures 18A-D, IN administration of rasagiline (2 mg/kg) also resulted in significantly increased levels of hippocampal 5-HT (see, Figure 18 A) and NE (see, Figure 18D), compared to PO delivery (see, Figures 18A and 18D, respectively), as well as in significant decrease in the 5-HT/5-HIAA ratio (see, Figure 18C).
EXAMPLE 6
In vivo studies of IN delivery of two formulations of rasagiline were conducted as follows. Rats were treated with various concentrations of rasagiline (0.24-6 mg/kg) IN and PO, for 4 hours. Control rats were given either saline for the IN regimen or highly purified water in oral regimen. The animals were sacrificed by decapitation, and striatum, hippocampus, cerebellum, liver and small intestine have been removed rapidly and frozen in liquid nitrogen for further analyses.
Dry powder formulation:
Calcium carbonate, Carboxy Methyl Cellulose (CMC) and Dextrose were tested as fillers (carriers). Rasagiline and the tested filler were mechanical grounded and mixed well for homogenous powder purpose. Rasagiline concentrations in the formulations were adjusted according to each experiment.
The formulation was transferred into an Intra-nasal device as depicted in Figure 19. This device was found to be effective for IM administration of solid formulations to rats. The powder is loaded where indicated by the arrow. The syringe is filled with air, compressed to a volume of 5 ml of air pressure. After inserting the tip to rat nostril, the valve opens and releases the air. The powder is released with the air pressure.
Liquid formulation:
Rasagiline was dissolved in Saline solution according to the tested concentrations. The solution has been introduced to the nostril rats with appropriate tip.
Effect of IN rasagiline powder formulations on striatal and hippocampal MAO-A activity
Figures 20A-B present the effect of the various powder formulations on striatal and hippocampal MAO-A activity. As shown therein, striatal and hippocampal MAO- A inhibition was significantly higher using dextrose as a filler in the powder IN formulation, compared to calcium carbonate and CMC.
Effect of IN rasagiline formulations (powder and liquid) on MAO-A and MAO-B activity in rat brain and periphery :
The effect of the different IN rasagiline formulations (powder and liquid) on
MAO inhibition in the striatum, liver and intestine was tested. Rats received vehicle (control) or a single administration of rasagiline (0.6 mg/kg) PO, or IN in powder or liquid formulations. MAO-A activity was determined in the striatum and the ratios of striatum/Liver (striatum/Intestine were calculated. Results represent mean + SEM (n=7- 9). *p<0.05 vs. PO-treated rats; # p<0.05 vs. IN liquid treated rats. MAO-B activity was also determined in striatum, liver and intestine. Results represent mean + SEM (n=7-9). * p<0.05 vs. PO-treated rats.
The data is presented in Figures 21A-C and Table 4 below
As shown in Figure 21A, striatal MAO-A inhibition was significantly higher using the powder I formulation, compared to the liquid formulation.
The MAO-A inhibition ratios of striatum/liver (Figure 21B) and striatum/intestine (Figure 21C) were also higher using the powder IN formulation, compared to the liquid IN formulation and to PO administration.
As shown in Table 4 below, striatal MAO-B was almost completely inhibited by rasagiline (0.6 mg/kg), using the powder or liquid IN formulations. Intestinal MAO-B inhibition was similar in both IN formulations of rasagiline, and was significantly lower, compared to PO drug administration.
Table 4
Figure imgf000046_0001
A dose-dependent effect of IN rasagiline in powder formulation on MAO-A inhibition was further tested, at drug concentrations of 0.24-6 mg/kg. Rats received vehicle (control) or various concentrations (0.24-6 mg/kg) of IN rasagiline in a powder formulation (dextrose). MAO-A activity was determined in striatum, hippocampus, liver and intestine.
The obtained data are presented in Figures 22A-D, and show that a single IN rasagiline administration of the powder formulation (0.24-6 mg/kg) dose-dependently inhibited MAO-A in the striatum, hippocampus, liver and intestine. At 0.6 mg/kg IN rasagiline in powder formulation, striatal and hippocampal MAO-A inhibitory values were: 61 % and 66 % of control, p<0.05, respectively, while liver and intestine MAO-A inhibitory values were only 44 % and 41 %, p<0.05, respectively. Powder formulation of IN rasagiline resulted in almost a complete inhibition of MAO-B in the striatum, hippocampus and liver (> 95 %) and about 70 % inhibition in the intestine (data not shown).
Effect of IN powder formulation of rasagiline administered to a single vs. two nostrils on MAO-A and MAO-B activity in rat brain and periphery:
Acute IN administration of a powder (dextrose) formulation of rasagiline (0.6 mg/kg) to a single (right side) vs. two nostrils of rats, was tested. MAO-A inhibition in rat brain and periphery was further examined. Rats received rasagiline (powder formulation, 0.6 mg/kg) either to single (right side) or two nostrils. MAO-A activity ratios of striatum/intestine and hippocampus/intestine were determined.
The obtained data is presented in Figure 23. As shown therein, MAO-A inhibition ratios of striatum/intestine and hippocampus/intestine were significantly higher in two nostrils, compared to single nostril administration of rasagiline (powder formulation). This indicates a considerable brain MAO-A inhibition, while the levels of peripheral MAO-A are relatively low. No difference in MAO-A inhibition was shown between right and left nostril, following single nostril IN administration of rasagiline (data not shown).
Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims. All publications, patents and patent applications mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention. To the extent that section headings are used, they should not be construed as necessarily limiting.

Claims

WHAT IS CLAIMED IS:
1. A method of treating motor and neuropsychiatric symptoms associated with Parkinson's disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of Rasagiline or a pharmaceutically acceptable salt thereof, wherein said administering is effected by intranasal administration.
2. A method of treating depression in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of Rasagiline or a pharmaceutically acceptable salt thereof, wherein said administering is effected by intranasal administration.
3. The method of claim 2, wherein said depression is associated with Parkinson's disease.
4. A method of treating a neuropsychiatric condition and/or a neurodegenerative condition in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of Rasagiline or a pharmaceutically acceptable salt thereof, wherein said administering is effected by intranasal administration.
5. The method of claim 4, wherein said condition is treatable by 1-(R)- aminoindan.
6. The method of any one of claims 1-5, wherein said amount of Rasagiline or a salt thereof is such that inhibits at least 50 % of an activity of MAO-A in the brain of the subject.
7. The method of claim 6, wherein said amount of Rasagiline or a salt thereof is such that inhibits at least 80 % of an activity of MAO-A in the brain of the subject.
8. The method of any one of claims 1 to 7, wherein said amount of Rasagiline or a salt thereof is such that a ratio of the inhibition of an activity of brain MAO-A to inhibition of an activity of peripheral MAO-A is higher than 1.
9. The method of any one of claims 1-8, wherein said Rasagiline or a salt thereof is administered as a pharmaceutical composition which further comprises a pharmaceutically acceptable carrier.
10. The method of claim 9, wherein said composition is in a form of a powder.
11. The method of claim 9 or 10, wherein said composition and/or a mode of said intranasal administration are configured such that following said administering, an amount of Rasagiline in the brain of the subject is such that inhibits at least 50 % or at least 80 % of an activity of MAO-A in the brain.
12. The method of claim 9 or 10, wherein said composition and/or a mode of said intranasal administration are configured such that following said administering, an amount of Rasagiline in the brain of the subject is such that a ratio of the inhibition of an activity of brain MAO-A to inhibition of an activity of peripheral MAO-A is higher than 1.
13. The method of any one of claims 1 to 12, wherein said amount of Rasagiline or a salt thereof ranges from an amount equivalent to 0.2 mg/kg per day to 6 mg/kg per day in rats.
14. The method of any one of claims 1 to 13, wherein said subject is a human and said amount of Rasagiline or a salt thereof is higher than 2 mg per day.
15. A pharmaceutical composition comprising Rasagiline or a pharmaceutically acceptable salt thereof, the composition being formulated for intranasal administration.
16. The composition of claim 15, being in a form of a powder.
17. A system for intranasal administration of Rasagiline or a pharmaceutically acceptable salt thereof to a subject in need thereof, the system comprising means for dispensing a pre-determined dose of Rasagiline or said salt thereof and for intranasally delivering said dose, said pre-determined dose being effective for alleviating neuropsychiatric and motor symptoms associated with Parkinson's disease.
18. A system for intranasal administration of Rasagiline or a pharmaceutically acceptable salt thereof to a subject in need thereof, the system comprising means for dispensing a pre-determined dose of Rasagiline or said salt thereof and for intranasally delivering said dose, said pre-determined dose being effective for treating neuropsychiatric and/or neurodegenerative conditions in a subject in need thereof.
19. The system of claim 18, wherein said pre-determined dose is effective for treating depression.
20. A method of treating a neuropsychiatric and/or neurodegenerative condition is a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of Rasagiline or a pharmaceutically acceptable salt thereof, wherein said administering is effected at a dose and/or a mode of administration selected such that a ratio of the inhibition of an activity of brain MAO-A to inhibition of an activity of peripheral MAO-A in the subject is higher than 1.
21. A system configured for administering Rasagiline or a pharmaceutically acceptable salt thereof to a subject in need thereof, the system comprising means for delivering Rasagiline or said salt thereof to the subject, wherein said means are such that upon delivering Rasagiline or said salt thereof, a ratio of the inhibition of an activity of brain MAO-A to inhibition of an activity of peripheral MAO-A in the subject is higher than 1.
PCT/IL2015/050267 2014-03-13 2015-03-12 Methods, compositions and devices for treatment of motor and depression symptoms associated with parkinson's disease WO2015136543A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IL2014/050282 WO2015136515A1 (en) 2014-03-13 2014-03-13 Methods, compositions and devices for treatment of motor and depression symptoms associated with parkinson's disease
ILPCT/IL2014/050282 2014-03-13

Publications (1)

Publication Number Publication Date
WO2015136543A1 true WO2015136543A1 (en) 2015-09-17

Family

ID=54071026

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/IL2014/050282 WO2015136515A1 (en) 2014-03-13 2014-03-13 Methods, compositions and devices for treatment of motor and depression symptoms associated with parkinson's disease
PCT/IL2015/050267 WO2015136543A1 (en) 2014-03-13 2015-03-12 Methods, compositions and devices for treatment of motor and depression symptoms associated with parkinson's disease

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/IL2014/050282 WO2015136515A1 (en) 2014-03-13 2014-03-13 Methods, compositions and devices for treatment of motor and depression symptoms associated with parkinson's disease

Country Status (1)

Country Link
WO (2) WO2015136515A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020214886A1 (en) * 2019-04-17 2020-10-22 Vici Health Sciences LLC Liquid pharmaceutical compositions

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015126944A1 (en) 2014-02-18 2015-08-27 Henkin Robert I Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
US11879115B2 (en) * 2018-11-26 2024-01-23 Roar Holding Llc Methods to improve beverage quality
WO2023133463A1 (en) * 2022-01-06 2023-07-13 Cyrano Therapeutics, Inc. Improved nasal administration of parkinson's therapeutics

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891923A (en) * 1990-01-03 1999-04-06 Teva Pharmaceutical Industries Ltd. R-enantiomer of N-propargyl-1-aminoindan for the treatment of dementia
WO2009003147A1 (en) * 2007-06-26 2008-12-31 Parkinson's Institute Methods and compositions for the treatment of neurological disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891923A (en) * 1990-01-03 1999-04-06 Teva Pharmaceutical Industries Ltd. R-enantiomer of N-propargyl-1-aminoindan for the treatment of dementia
WO2009003147A1 (en) * 2007-06-26 2008-12-31 Parkinson's Institute Methods and compositions for the treatment of neurological disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
P. R. RAVI ET AL.: "Nasal in-situ gels for delivery of rasagiline mesylate: improvement in bioavailability and brain localization", DRUG DELIV, EARLY, 29 November 2013 (2013-11-29) *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020214886A1 (en) * 2019-04-17 2020-10-22 Vici Health Sciences LLC Liquid pharmaceutical compositions
US11701340B2 (en) 2019-04-17 2023-07-18 Vici Health Sciences., Llc Liquid pharmaceutical compositions

Also Published As

Publication number Publication date
WO2015136515A1 (en) 2015-09-17

Similar Documents

Publication Publication Date Title
Wellington et al. Venlafaxine extended-release: a review of its use in the management of major depression
EP1991214B1 (en) Use of rasagiline for the treatment of multiple system atrophy
Feighner et al. Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression
JP5563461B2 (en) 1-amino-alkylcyclohexane derivatives for the treatment of cochlear tinnitus
US20230355575A1 (en) Mdma prodrugs to assist psychotherapy
WO2015136543A1 (en) Methods, compositions and devices for treatment of motor and depression symptoms associated with parkinson&#39;s disease
US20170151192A1 (en) Methods, compositions and devices for treatment of motor and depression symptoms associated with parkinson&#39;s disease
CN110996947A (en) Combination therapy for neuropsychiatric diseases responsive to glutamate receptor antagonists of the N-methyl-D-aspartate type
US20230233688A1 (en) Mdma prodrugs to assist psychotherapy
JP5842058B2 (en) Clenbuterol for use in the treatment of autism
US20240050454A1 (en) Compositions and Methods For Treating Neurological Conditions
US20190350914A1 (en) Pridopidine for treating drug induced dyskinesias
JP6084931B2 (en) Neramexane for the treatment or prevention of tinnitus associated with stress or acute hearing loss
US20220409579A1 (en) Methods of treating binge eating disorder
Reichmann Budipine in Parkinson's tremor
US11826326B2 (en) Benzoic acid or a salt and derivative thereof for use in preventing or treating depression
Sharma et al. Amine precursors in depressive disorders and the blood-brain barrier
US20210275512A1 (en) Pridopidine for treating drug induced dyskinesias
WO2023112024A1 (en) Method of treating parkinson&#39;s disease
US20230248737A1 (en) Compositions and methods for treating psychiatric disorders or symptoms thereof
RU2446794C2 (en) Interval therapy for treating tinnitus
KR20160146872A (en) Drug for treatment of tinnitus patients

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15760982

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 02/01/2017)

122 Ep: pct application non-entry in european phase

Ref document number: 15760982

Country of ref document: EP

Kind code of ref document: A1